Reactor Type	Anodic Supporting Materials	Cathode Materials	Power Density (mW m−2)	Comparision to Pt/C or Bare Materials	Ref.

250 mL double chambers	Graphite granule	Pt/C	1470 ± 10	-	[35]

250mL double chambers	Graphite granule	Co3O4/N doped graphene	1340 ± 10	Comparable to Pt/C	[35]

6 mL single chamber	Carbon paper	Co/Fe/N/CNTs	751	1.5 times > Pt/C	[36]

80 mL double chamber	Carbon fiber	N-doped CNTs on C cloth	1600 ± 50	12.8% > Pt/C	[37]

Single chamber	Carbon felts	Fe–N-functionalized graphene	1149.8	2.1 times > Pt/C	[38]

Single chamber	Carbon cloth	Graphene supported Pt–Co	1378	Comparable to Pt/C	[39]

Sediment MFCs	Graphite felt	Polyaniline-Graphene nanosheets	99	116 times > Graphite	[40]

Double chamber	-	N/S co-doped carbon nanosheets	1500	Comparable to Pt/C	[41]

15 mL sediment single chamber	MWNT coating Graphite	MWNT coating Graphite	214.7 ± 9.9	1.6 times higher than that of bare graphite	[42]

Single chamber	Carbon cloth	Graphene/poly(3,4-ethylenedioxythiophene)/Fe3O4	3525	8.2 times > Carbon cloth	[43]

Double chamber	Carbon brush	N-doped Graphene/CoNi alloy encased within bamboo-like CNTs	2000	Comparable to Pt/C	[44]

210 mL double chamber	Carbon paper	CNTs/Polypyrrole	113.5	Comparable to Pt/C	[45]

Single chamber	Graphite fiber brush	Ag/Fe/N/C	1791	1.5 times > Pt/C	[46]

20 mL single chamber	N-Ni-carbon nanofibers	N-doped polymer-Ni–carbon nanofibers	1690 ± 30	-	[47]

1.5 L single chamber	Carbon fiber	Co-doped Carbon nanofibers	92	Stable more than 6000 h	[48]


		NaCl (n = 12)	TCA (n = 9)	p

direct treatment response	no response	8	2

	partial response, not satisfactory	1	0

	partial response, satisfactory	2	1

	complete resolution of symptoms	1	6

				0.015*

mean severity of pain in the past week (95% CI)		4.3 (2.3-6.3)	1.3 (0.3-2.9)

	mean rank	13.1	7.4	0.031§

mean Dutch AIMS-2-HFF (95% CI)		2.7 (1.9-3.6)	1.9 (0.7-3.2)

	mean rank	12.4	8.2	0.112§

patient perceived improvement	much worse	0	0

	worse	2	0

	not better not worse	6	2

	better	1	1

	much better	3	6

				0.047*

		NaCl (n = 12)	TCA (n = 9)	p

direct treatment response	no response	8	2

	partial response, not satisfactory	1	0

	partial response, satisfactory	2	1

	complete resolution of symptoms	1	6

				0.015*

		4.3 (2.3-	1.

		NaCl (n = 12)	TCA (n = 9)	p

mean severity of pain in the past week (95% CI)		6.3)	3 (0.3-2.9)

	mean rank	13.1	7.4	0.031§

mean Dutch AIMS-2-HFF (95% CI)		2.7 (1.9-3.6)	1.9 (0.7-3.2)

	mean rank	12.4	8.2	0.112§

patient perceived improvement	much worse	0	0

	worse	2	0

	not better not worse	6	2

	better	1	1

	much better	3	6

				0.047*


	Total group n = 72	Controls n = 36	CVD patients n = 36	p value

Characteristics

Age (years)	60 ± 7	59 ± 7	61 ± 6	0.41

Body height (cm)	178 ± 7	180 ± 7	176 ± 6	0.011

Body mass (kg)	81 ± 11	81 ± 11	81 ± 12	0.98

Body Mass Index (kg/m2)a	25.3 [23.6 to 27.0]	24.9 [23.3 to 26.9]	25.6 [24.2 to 27.9]	0.20

Mean arterial pressure (mmHg)a	97 [91 to 105]	100 [93 to 106]	94 [90 to 100]	0.035

Diastolic blood pressure (mmHg)a	79 [75 to 88]	83 [77 to 91]	77 [73 to 82]	0.011


After the Onset

	Value	Std.Error	df	t-value	p-value

(Intercept)	22.00	3.37	4553	6.53	<0.0001

AUT	16.58	4.90	26	3.39	0.0023

After the Onset

	Value	Std.Error	df	t-value	p-value

AUT	16.58	4.90	26	3.39	0.0023


Dataset

CMap Build 02

HT-HG-U133A

Batch Correction

Non-Silent Drugs

Merge Replicates


Variable	Aromatherapy group	Control group	p-value

Standard deviation and mean of mothers' age (year)	26.43±3.216	26.60±3.406	0.768

Educationhigh school and loweruniversity degree	79.4%20.6%	82.5%17.5%	0.967

ProfessionHousewifeWorking	79.4%20.6%	82.5%17.5%	0.650

Husband's Educationhigh school and loweruniversity degree	84.2%15.8%	87.3%12.7%	0.895

Husband's professionUnemployedFree workemploee	14.3%69.8%15.9%	12.7%69.8%17.5%	0.948

Standard deviation and mean of pregnancy age(week)	38.30±0.978	38.08±1.067	0.225

Wanted pregnancy	79.4%	82.5%	0.650

Receiving prenatal careYesNo	92.5%4.8%	96.8%3.2%	0.650

Type of childbirthNormal vaginal deliveryCesarian section	98.4%1.6%	96.8%3.2%	0.561

Standard deviation and mean ofcontraction length in 3-4 cm dilatation	44.08±0.703	43.94±0.759	0.275

Standard deviation and mean of contraction length in 5-7 cm dilatation	47.40±0.493	47.27±0.447	0.133

Standard deviation and mean of contraction length in8-10 cm dilatation	49.44±0.501	49.43±0.499	0.859

Standard deviation and mean of contraction frequency during 10 minutes in 3-4 cm dilatation	2.27±0.447	2.27±0.447	1.000

Standard deviation and mean of contraction frequency during 10 minutes in 5-7 cm dilatation	3.16±0.368	3.22±0.419	0.368

Standard deviation and mean of contraction frequency during 10 minutes in 8-10 cm dilatation	3.81±0.396	3.73±0.447	0.294

Variable	Aromatherapy group	Control group	p-value

Husband's professionUnemployedFree workemploee	14.3%69.8%15.9%	12.7%69.8%17.5%	0.948

Standard deviation and mean of pregnancy age(week)	38.30±0.978	38.08±1.067	0.225

Wanted pregnancy	79.4%	82.5%	0.650

Receiving prenatal careYesNo	92.5%4.8%	96.8%3.2%	0.650

Type of childbirthNormal vaginal deliveryCesarian section	98.4%1.6%	96.8%3.2%	0.561

Standard deviation and mean ofcontraction length in 3-4 cm dilatation	44.08±0.703	43.94±0.759	0.275

Standard deviation and mean of contraction length in 5-7 cm dilatation	47.40±0.493	47.27±0.447	0.133

Standard deviation and mean of contraction length in8-10 cm dilatation	49.44±0.501	49.43±0.499	0.859

Standard deviation and mean of contraction frequency during 10 minutes in 3-4 cm dilatation	2.27±0.447	2.27±0.447	1.000

Standard deviation and mean of contraction frequency during 10 minutes in 5-7 cm dilatation	3.16±0.368	3.22±0.419	0.368

Standard deviation and mean of contraction frequency during 10 minutes in 8-10 cm dilatation	3.81±0.396	3.73±0.447	0.294


Variables Separated by Category 1	Number of Responses/Number Total	Number Relative (%)

Lives near areas of vegetation

Yes	449/478	93.9 *

No	29/478	6.1

Destination of Household Waste

Garbage truck	288/478	60.3 *

Local dump site	6/478	1.3

Garbage truck and other destinations	184/478	38.5

Lives near open-air garbage dump

Yes	366/478	76.6 *

No	112/478	23.4

Disposal of domestic sewage

Mossoró River	213/478	44.6 *

Sanitation system	181/478	37.9

Sink	70/478	14.6

Sink and Mossoró River	8/478	1.7

Unknown	6/478	1.3

Vegetation around residence

Fruit trees	135/478	28.2

Other types of vegetation	166/478	34.7

Does not have vegetation	177/478	37.0

Presence of mosquitoes in house

Yes	412/478	86.2 *

No	66/478	13.8

Increase in mosquitoes in the rainy season

Yes	399/478	83.5 *

No	79/478	16.5

Repellent plants/insecticides used near home

Yes	15/478	3.1

No	463/478	96.9 *


Group	IC50 (μmol/L)	RR

EST1 siRNA	34.63 ± 1.29*	2.35

Negative control siRNA	86.18 ± 5.29	0.94

Control untransfected	81.37 ± 6.34	1.00


Strain	Growth rate	min Nar	max Nar	Distance to WT	p-value	q-value	Method

	(h−1)	(mmol/gDCW/h)	(mmol/gDCW/h)	(mmol/gDCW/h)


Predicted Variables (Y)	Variable Selection (Variables Left in the Model with p < 0.05)	Prediction Equations (Test Model: Y = a + b1x1 + b2x2)	Model R2 Value	RSD a	p Value

Carbohydrate fraction profiles

CA4 (% CHO)	Ratio of structural CHO to total CHO left in the model	Y = −41.04 + 99.32 A_StCHO/A_CHO ratio	0.77	1.00	0.022

CB1 (% CHO)	H_1415 left in the model	Y = −6.91 + 355.77 H_1415	0.70	0.97	0.038

CB3 (% CHO)	H_895 left in the model	Y = 42.57 − 4338.00 H_895	0.91	0.64	0.004

Total digestible nutrients

tdNDF (% DM)	A_non-STCHO left in the model	Y = 21.84 − 83.78 A_non-STCHO	0.88	0.28	0.006


Kinase	Activity %	Kinase	Activity %	Kinase	Activity %

CK2α2β2	10	PKCa	95	TAK1	107

CK2α	42	IRAK4	95	CDK9-Cyclin T1	108

PIM3	62	HIPK3	96	RSK1	108

MLK3	63	JNK3	96	MPSK1	108

CK1δ	72	IGF-1R	96	RSK2	108

BRK	72	VEG-FR	96	DDR2	109

PLK1	75	IRAK1	97	EPH-A2	110

MST2	77	MAPKAP-K2	97	MNK1	110

MST4	78	PAK5	97	PKCγ	110

CHK2	80	IKKe	97	CHK1	111

MKK1	81	GSK3b	98	OSR1	111

TrkA	81	DYRK1A	98	JNK2	112

PKBb	81	MAPKAP-K3	98	STK33	112

CAMK1	82	MSK1	99	NEK6	112

MKK2	82	AMPK (hum)	99	IKKb	112

ABL	82	SYK	99	EIF2AK3	112

PDK1	83	PDGFRA	99	p38g MAPK	114

MAP4K3	84	LKB1	99	MKK6	114

MLK1	84	p38a MAPK	99	ZAP70	114

PIM1	85	HIPK2	99	p38b MAPK	114

FGF-R1	85	HER4	100	CSK	114

MAP4K5	86	MARK2	100	TTBK1	115

PAK6	87	TTBK2	100	Aurora A	115

TIE2	88	EPH-B2	101	TAO1	115

MNK2	88	TTK	101	MEKK1	115

SIK2	89	ULK2	101	MELK	116

MARK3	89	WNK1	101	SRPK1	117

YES1	89	ERK8	102	EPH-B3	117

GCK	90	PINK	102	PRK2	118

ERK1	90	PKCz	102	PIM2	120

TESK1	90	PAK4	102	IRR	120

PKBa	91	JAK2	102	ASK1	120

DYRK2	91	MARK4	103	p38d MAPK	120

SGK1	91	BRSK1	103	PKA	121

CK1γ2	91	PRAK	103	CDK2-Cyclin A	121

S6K1	91	RIPK2	103	Lck	122

CLK2	91	TBK1	103	HIPK1	123

SmMLCK	92	DYRK3	104	BTK	125

JNK1	92	NUAK1	104	EPH-A4	126

ULK1	92	NEK2a	105	TLK1	126

Aurora B	93	SIK3	105	MST3	126

DAPK1	93	ROCK 2	105	IR	128

ERK2	94	MINK1	105	TGFBR1	130

CAMKKb	94	ERK5	106	TSSK1	131

EF2K	94	EPH-B1	106	EPH-B4	132

BRSK2	95	PAK2	106

PKD1	95	MARK1	106

Src	95	PHK	107

Kinase	Activity %	Kinase	Activity %	Kinase	Activity %

CK2α2β2	10	PKCa	95	TAK1	107

CK2α	42	IRAK4	95	CDK9-Cyclin T1	108

PIM3	62	HIPK3	96	RSK1	108

MLK3	63	JNK3	96	MPSK1	108

CK1δ	72	IGF-1R	96	RSK2	108

BRK	72	VEG-FR	96	DDR2	109

PLK1	75	IRAK1	97	EPH-A2	110

MST2	77	MAPKAP-K2	97	MNK1	110

MST4	78	PAK5	97	PKCγ	110

CHK2	80	IKKe	97	CHK1	111

MKK1	81	GSK3b	98	OSR1	111

TrkA	81	DYRK1A	98	JNK2	112

PKBb	81	MAPKAP-K3	98	STK33	112

CA	82	M	99	NEK	1

Kinase	Activity %	Kinase	Activity %	Kinase	Activity %

MK1		SK1		6	12

MKK2	82	AMPK (hum)	99	IKKb	112

ABL	82	SYK	99	EIF2AK3	112

PDK1	83	PDGFRA	99	p38g MAPK	114

MAP4K3	84	LKB1	99	MKK6	114

MLK1	84	p38a MAPK	99	ZAP70	114

PIM1	85	HIPK2	99	p38b MAPK	114

FGF-R1	85	HER4	100	CSK	114

MAP4K5	86	MARK2	100	TTBK1	115

PAK6	87	TTBK2	100	Aurora A	115

TIE2	88	EPH-B2	101	TAO1	115

MNK2	88	TTK	101	MEKK1	115

SIK2	89	ULK2	101	MELK	116

MARK3	89	WNK1	101	SRPK1	117

YES1	89	ERK8	102	EPH-B3	117

GCK	90	PINK	102	PRK2	118

ERK1	90	PKCz	102	PIM2	120

TESK1	90	PAK4	102	IRR	120

PKBa	91	JAK2	102	ASK1	120

DYRK2	91	MARK4	103	p38d MAPK	120

SGK1	91	BRSK1	103	PKA	121

CK1γ2	91	PRAK	103	CDK2-Cyclin A	121

S6K1	91	RIPK2	103	Lck	122

CLK2	91	TBK1	103	HIPK1	123

SmMLCK	92	DYRK3	104	BTK	125

JNK1	92	NUAK1	104	EPH-A4	126

ULK1	92	NEK2a	105	TLK1	126

Aurora B	93	SIK3	105	MST3	126

DAPK1	93	ROCK 2	105	IR	128

ERK2	94	MINK1	105	TGFBR1	130

CAMKKb	94	ERK5	106	TSSK1	131

EF2K	94	EPH-B1	106	EPH-B4	132

BRSK2	95	PAK2	106

PKD1	95	MARK1	106

Src	95	PHK	107


Operator	Sagittal* (degrees)	Coronal** (degrees)	Horizontal*** (degrees)


Grading	Description

0	No apparent EB extravasation

1	A small amount of EB extravasation within the cerebral cortex

2	Flake dispersion of EB at the lateral ventricle or hippocampal layer

3	Massive EB extravasation in the brain tissue

Description

No apparent EB extravasation

A small amount of EB extravasation within the cerebral cortex

Flake dispersion of EB at the lateral ventricle or hippocampal layer

Massive EB extravasation in the brain tissue


LBI	Peak method*

≥ LLQ	≥ LLD

Min	Max	Min	Max

Oxford	97,		33,768	1


Participant	Form of feedback	Total number

General practitioner	One-on-one interview	4

GP registrar	Focus group	1 group with 14 attendees

General practitioner	Focus group	3 groups (3 GPs, 4 GPs, 4 GPs)

Healthcare consumer representative	One-on-one interview	5

Representative bodies for chronic illness	One-on-one interview	2

Dietician	One-on-one interview	1

Psychologist	One-on-one interview	1

		Total—38

Participant	Form of feedback	Total number

GP registrar	Focus group	1 group with 14 attendees

General practitioner	Focus group	3 groups (3 GPs, 4 GPs, 4 GPs)

Healthcare consumer representative	One-on-one interview	5

Representative bodies for chronic illness	One-on-one interview	2

Dietician	One-on-one interview	1

Psychologist	One-on-one interview	1

		Total—38


Lead Author	Year	Journal	Detection Rate	Accuracy Rate	Sensitivity Rate	False Negative Rate	Negative Predictive Value	Upstaging Rate

Saha (a)[47]	2000	Ann Surg Oncol	99	96	91	9	Ns	18

Wiese (a)[48]	2000	Arch Pathol Lab Med	99	96	91	9	ns	ns

Waters (b)[49]	2000	Am Surg	91	100	100	0	100	6

Bilchik (c)[50]	2001	J Clin Oncol	100	100	100	0	100	50

Paramo (d)[51]	2001	Am J Surg	71	100	100	0	100	11

Wood (a)+(c)[52]	2001	Ann Surg Oncol	96	95	88	12	ns	25

Wood (c)[53]	2001	Surg Endosc	100	100	100	0	100	9

Saha (a)+(c)[54]	2001	Ann Surg Oncol	98	96	90	10	95	14

Esser [55]	2001	Dis Colon Rectum	58	94	67	33	94	7

Bendavid [56]	2002	J Surg Oncol	90	94	95	5	91	42

Paramo (d)[57]	2002	Ann Surg Oncol	82	98	93	7	97	11

Wood (c)[58]	2002	J GastroInt Surg	97	95	92	8	ns	24

Bilchik (c)[59]	2002	Eur J Cancer	97	95	91	5	ns	24

Kitagawa [60]	2002	Dis Colon Rectum	91	92	82	18	88	ns

Feig (e)[61]	2002	Am J Surg	98	79	38	62	76	8

Broderick-Villa [62]	2002	Cancer J	92	79	50	50	73	0

Tsioulias (c)[63]	2002	Am Surg	100	93	67	33	ns	15

Nastro [64]	2002	Tumori	75	100	100	0	100	ns

Bilchik (c)[65]	2003	Cancer Control	100	93	91	9	ns	14

Cox [66]	2003	Curr Surg	100	100	100	0	100	29

Bilchik (c)[67]	2003	J Clin Oncol	96	96	92	8	ns	29

Turner (c)[68]	2003	Archives Path	82	92	87	13	ns	29

Trocha (a)+(c)[69]	2003	J GastroInt Surg	98	95	84	16	93	21

Veihl [70]	2003	World J Surg	87	78	50	22	71	11

Levine (b)[71]	2003	J GastroInt Surg	92	ns	50	ns	86	ns

Saha (a)[72]	2004	Dis Colon Rectum	99	ns	88	12	ns	13

Dan (a)[73]	2004	Arch Surg	99	96	86	16	ns	5

Braat [21]	2004	Eur J Surg Oncol	94	97	80	20	92	3

Bertoglio [74]	2004	J Surg Oncol	95	92	78	22	88	ns

Read [75]	2004	Dis Colon Rectum	79	97	25	75	ns	3

Patten (e)[76]	2004	Cancer	98	89	83	17	76	20

Bertagnolli [77]	2004	Ann Surg	92	80	46	54	75	0

Saha (a)[78]	2004	Ann Surg Oncol	100	95	84	16	93	5

Saha (a)[79]	2004	Semin Oncol	100	96	92	8	ns	13

Bembenek (f)[80]	2005	World J Surg	85	ns	92	8	95	26

Codnignola [81]	2005	JJ Clin Oncol	100	ns	72	28	70	37

Dahl [82]	2005	Eur J Surg Oncol	100	92	83	17	91	ns

Bilchik (a)+(c)[83]	2006	Arch Surg	100	95	88	12	ns	23

Tuech [84]	2006	Eur J Surg Oncol	97	94	91	9	ns	ns

Saha (a)[85]	2006	Am J Surg	98	96	90	10	93	ns

Kelder (g)[86]	2006	Scand J Gastroenterol	97	93	86	14	89	33

Thomas (b)[87]	2006	Am Surg	93	20	46	54	73	5

Covarelli [88]	2006	Am Surg	95	95	86	14	ns	8

Kelder (g)[89]	2007	Int J Col Dis	97	96	89	11	93	ns

Bianchi [90]	2007	Surg End	100	95	83	17	94	9

Murawa [91]	2007	Acta Chir Belg	93	84	83	17	ns	8

Bembenek (f)[92]	2007	Ann Surg	85	86	54	46	80	21

Sandrucci [93]	2007	J Surg Oncol	100	91	92	9	ns	11

Tiffet [94]	2007	Dis Colon Rectum	92	81	80	20	74	ns

Lim (e)[95]	2008	Ann Surg Oncol	99	83	59	41	78	ns

Kusano [96]	2008	Digestive Surgery	88.5	82.6	33	67	81	ns

Quadros [97]	2008	J Surg Oncol	91	80	67	33	67	25

Journal	Detection Rate	Accuracy Rate	Sensitivity Rate	False Negative Rate	Negative Predictive Value	Upstaging Rate

Ann Surg Oncol	99	96	91	9	Ns	18

Arch Pathol Lab Med	99	96	91	9	ns	ns

Am Surg	91	100	100	0	100	6

J Clin Oncol	100	100	100	0	100	50

Am J Surg	71	100	100	0	100	11

Ann Surg Oncol	96	95	88	12	ns	25

Surg Endosc	100	100	100	0	100	9

Ann Surg Oncol	98	96	90	10	95	14

Dis Colon Rectum	58	94	67	33	94	7

J Surg Oncol	90	94	95	5	91	42

Ann Surg Oncol	82	98	93	7	97	11

J GastroInt Surg	97	95	92	8	ns	24

Eur J Cancer	97	95	91	5	ns	24

Dis Colon Rectum	91	92	82	18	88	ns

Am J Surg	98	79	38	62	76	8

Cancer J	92	79	50	50	73	0

Am Surg	100	93	67	33	ns	15

Tumori	75	100	100	0	100	ns

Cancer Control	100	93	91	9	ns	14

Curr Surg	100	100	100	0	100	29

J Clin Oncol	96	96	92	8	ns	29

Archives Path	82	92	87	13	ns	29

J GastroInt Surg	98	95	84	16	93	21

World J Surg	87	78	50	22	71	11

J GastroInt Surg	92	ns	50	ns	86	ns

Dis Colon Rectum	99	ns	88	12	ns	13

Arch Surg	99	96	86	16	ns	5

Eur J Surg Oncol	94	97	80	20	92	3

J Surg Oncol	95	92	78	22	88	ns

Dis Colon Rectum	79	97	25	75	ns	3

Cancer	98	89	83	17	76	20

Ann Surg	92	80	46	54	75	0

Ann Surg Oncol	100	95	84	16	93	5

Semin Oncol	100	96	92	8	ns	13

World J Surg	85	ns	92	8	95	26

JJ Clin Oncol	100	ns	72	28	70	37

Eur J Surg Oncol	100	92	83	17	91	ns

Arch Surg	100	95	88	12	ns	23

Eur J Surg Oncol	97	94	91	9	ns	ns

Am J Surg	98	96	90	10	93	ns

Scand J Gastroenterol	97	93	86	14	89	33

Am Surg	93	20	46	54	73	5

Am Surg	95	95	86	14	ns	8

Int J Col Dis	97	96	89	11	93	ns

Surg End	100	95	83	17	94	9

Acta Chir Belg	93	84	83	17	ns	8

Ann Surg	85	86	54	46	80	21

J Surg Oncol	100	91	92	9	ns	11

Dis Colon Rectum	92	81	80	20	74	ns

Ann Surg Oncol	99	83	59	41	78	ns

Digestive Surgery	88.5	82.6	33	67	81	ns

J Surg Oncol	91	80	67	33	67	25


Antibiotic	MBEC (−Streptokinase) (mg/L)	MBEC (+Streptokinase) (mg/L)

Daptomycin	1024	1024

Daptomycin + rifampicin	64	<4

Vancomycin	128	64

Vancomycin + rifampicin	64	4

Antibiotic	MBEC (−Streptokinase) (mg/L)	MBEC (+Streptokinase) (mg/L)

Vancomycin	128	64

Vancomycin + rifampicin	64	4


Variable	First assessment	Second assessment	p value

Mean	95% CI	Mean	95% CI

Adjusted age	10.9	10.1–10.7	19.9	19.1–20.7	<0.001


Item	Brucellosis	Leptospirosis

Cases (%)	95% CI	Cases (%)	95% CI

ju-Island		.3-1.9	2)	-

Total	651		1,153


Operator\device	1	2

1	SEN = 75%	SEN = 68%

SPC = 82%	SPC = 61%

2	SEN = 68%	SEN = 58%

SPC = 59%	SPC = 70%


Stimulation	Overexpressed in BCG-vaccinated infants	Median fold change	Under-expressed in BCG-vaccinated infants	Median fold change

Mtb lysate	IL-2, IFNγ, IL-13, IL-1α, IP-10, IL-6	>10

Flt-3L, IL-8, IL-1Rα, IL-12p40, IL-10, MCP-3	5–10

MIP-1α, IL-5, TNFα, VEGF, MIP-1β, GM-CSF, IL-7, IL-17, IFNα2, eotaxin	2–5

CD40L, TNFβ, fractalkine, FGF- 2, TGFα	1–2

Pam3Cys	IL-10, epidermal growth factor (EGF)	5–10

Platelet-derived growth factor (PDGF)-AB/BB, sCD40L, MIP-1α	2–5

IL-12p40, IL-6, MCP-3, IL-7, eotaxin	1–2

Candida albicans	EGF, IL-6, PDGF-AB/BB, MCP-3	2–5	IL-2, IL-13, IL-17, IP-10	0.2–0.5

Staphylococcus aureus	EGF, IL-6	2–5

PDGF-AB/BB	1.7

Escherichia coli	EGF	2.8	GM-CSF, GRO	0.2–1.0

Lipopolysaccharide	IL-8	1.7	GM-CSF, GRO	0.2–1.0

Stimulation	Overexpressed in BCG-vaccinated infants	Median fold change	Under-expressed in BCG-vaccinated infants	Median fold change

Lipopolysaccharide	IL-8	1.7	GM-CSF, GRO	0.2–1.0


GI name	tRNA gene (gene_ID)	GI-left end	GI-right end	GI-length (bp)	GC%	duplication length (bp)	gene_ID of integrase

BJ6TGI01	trnR-CCG (BJ6T08940)	911,924	937,940	26,017	55.7	50	BJ6T08690


mRNA	Primer

Mouse B2m	Fwd 5′-ACCGTCTACTGGGATCGAGA-3′

	Rev 5′-TGCTATTTCTTTCTGCGTGCAT-3′

Mouse Rpl13a	Fwd 5′-AGAAGCAGATCTTGAGGTTACGG-3′

	Rev 5′-GTTCACACCAGGAGTCCGTT-3′

Mouse Aqp5	Fwd 5′-CTTGTGGGGATCTACTTCACCG-3′

	Rev 5′-AAGTAGAGGATTGCAGCCAGG-3′

Mouse T1α	Fwd 5′-TCACCCCAATAGAGATGGCTTG-3′

	Rev 5′-GGGCAAGTTGGAAGCTCTCTT-3′

Mouse Rage	Fwd 5′-CACAGGCTCTGTGGGTGAG-3′

	Rev 5′-TTCAGCTCTGCACGTTCCTC-3′

Mouse Con43	Fwd 5′-TCCTTTTCCTTTGACTTCAGCCTC-3′

	Rev 5′-TCTGAAAATGAAGAGCACCGACA-3′

Mouse Sftpc	Fwd 5′-GGAGCACCGGAAACTCAGAA-3′

	Rev 5′-GGAGCCGCTGGTAGTCATAC-3′

mRNA

Mouse B2m

Mouse Rpl13a

Mouse Aqp5

Mouse T1α

Mouse Rage

Mouse Con43

Mouse Sftpc

Primer

Fwd 5′-ACCGTCTACTGGGATCGAGA-3′

Rev 5′-TGCTATTTCTTTCTGCGTGCAT-3′

Fwd 5′-AGAAGCAGATCTTGAGGTTACGG-3′

Rev 5′-GTTCACACCAGGAGTCCGTT-3′

Fwd 5′-CTTGTGGGGATCTACTTCACCG-3′

Rev 5′-AAGTAGAGGATTGCAGCCAGG-3′

Fwd 5′-TCACCCCAATAGAGATGGCTTG-3′

Rev 5′-GGGCAAGTTGGAAGCTCTCTT-3′

Fwd 5′-CACAGGCTCTGTGGGTGAG-3′

Rev 5′-TTCAGCTCTGCACGTTCCTC-3′

Fwd 5′-TCCTTTTCCTTTGACTTCAGCCTC-3′

Rev 5′-TCTGAAAATGAAGAGCACCGACA-3′

Fwd 5′-GGAGCACCGGAAACTCAGAA-3′

Rev 5′-GGAGCCGCTGGTAGTCATAC-3′


Base case ICER calculations	Threshold analysis*: probability of cost-effective at alternative values of willingness to pay for a QALY(%)

	Mean total cost (£)	Incremental cost (£)	Mean QALY	Incremental QALY	ICER (£/QALY)	£10,000	£20,000	£30,000	£50,000

Fluid loading	10,373		0.3527			84.4	86.5	89.4	92.0

Fluid control	11,739	-1,366	0.3175	0.0352	Dominated	15.6	13.5	10.6	8.0

Adjusted differences(95% CI; P-value)*		-2,047(-6,947 to 2,854; P = 0.413)		0.0431(-0.0171 to 0.1033; P = 0.161)


Name	Sequence	Genome Position*	Expected Size (bp)	Reference

p20F	5' ACAATATGCGAGCTTACTTTA 3' 	17691–17710	555	[18]

p20R	5' AACCTACACGCAAGATGGA 3' 	18229–18246

p23F	5' GTCTCTCCATCTTGCGGTGTAG 3'	18224–18244	733	[30]

p23R	5' CAATCAGATGAAGTGGTG3' 	18941–18957

p25F	5' TGAATTATGGACGACGAAAC 3'	16079–16097	676

p25R	5' TCAACGTGTGTTGAATTTCCC 3'	16736–16755

Name	Sequence	Genome Position*	Expected Size (bp)	Reference

p23F	5' GTCTCTCCATCTTGCGGTGTAG 3'	18224–18244	733	[30]

p23R	5' CAATCAGATGAAGTGGTG3'	18941–18957

p25F	5' TGAATTATGGACGACGAAAC 3'	16079–16097	676

p25R	5' TCAACGTGTGTTGAATTTCCC 3'	16736–16755


Plant material	Deposit number	Deposit location	Name of herbarium

Piper aduncum	10,480	INPA1	INPA herbarium

Piper tuberculatum	6,797	IFAM2	EAFM herbarium

Piper hispidum	6,796	IFAM	EAFM herbarium

Piper marginatum	6,798	IFAM	EAFM herbarium

Piper callosum	6,794	IFAM	EAFM herbarium

Piper hispidinervum	 	IFAM	EAFM herbarium

Piper sp.	 	IFAM	EAFM herbarium


Annual drug expenses (USD) (n = 116), mean ± SD	T	p value

Preoperative	660.08 ± 426.05	14.877	<0.001

Postoperative 1 year	65.12 ± 138.23

Difference in expenses	594.96 ± 430.74

Annual drug expenses (USD) (n = 116), mean ± SD	T	p value

Postoperative 1 year	65.12 ± 138.23	14.877	<0.001

Difference in expenses	594.96 ± 430.74


ICD-10 code	Criteria for Appropriate Antibiotic Prescription

H65 Nonsuppurative otitis mediaH66 Suppurative and nonspecified otitis media	H65 must meet both conditions: presence of Acute Bilateral Otitis media AND age < 2H65 or H66 with presence of otorrhea

J01 Acute sinusitis	Must meet all conditions: Fever of >38C°, purulent discharge and facial pain

JO2 Acute pharyngitisJO3 Acute tonsillitis	Must meet 3 of the following CENTOR criteria: Presence of tonsilar exudate Presence of painful anterior cervical lymphadenopathy or lymphadenitis Fever (> 38°) Absence of cough

JOO Acute nasopharyngitis [common cold]JO1 Acute sinusitisJO2 Acute pharyngitisJO3 Acute tonsillitisJO4 Acute laryngitis and tracheitisJO5 Acute obstructive laryngitis [croup] and epiglotitisJO6 Acute upper respiratory infections of multiple and unspecified sitesJ10 Influenza due to other identified influenza virusJ11 Influenza due to unidentified influenza virus	Must meet any of the following criteria: Presence of one or more of the following comorbidities: Cardiac, Pulmonary, Renal, Hepatic, Neuromuscular, Immunosuppression, Cystic Fibrosis, Diabetes Mellitus.- OR Age < 2 years old AND history of prematurityOR Age > 65 years old AND presence of cough AND two or more of the following:▪ Hospitalized in 2014▪ Diabetes mellitus▪ History of cardiac arrest▪ Current use of corticosteroidsOR Age > 80 years old AND presence of cough AND one or more of the following:▪ Hospitalized in 2014▪ Diabetes mellitus▪ History of cardiac arrest▪ Current use of corticosteroids


Preparedness	Female	Male

Personal:

Yes	8	19

No	11	7

Uncertain	3	4

Community:

Yes	5	5

No	11	15

Uncertain / Improving	0	6

Preparedness

Personal:

Yes

No

Uncertain

Community:

Yes

No

Uncertain / Improving


Filtered times	Repeat	Contigs (kb)	Accuracy (%)	Genome coverage (%)

TRC	CNRC	NNC	N50	Max 	CN-accuracy	Rep-accuracy	C-accuracy

1	11	Appendix	801	0.3	2.3	100	66.8	100	53.4

2	12	Appendix	418	1.8	7.6	100	82.1	100	101.9

3	13	Appendix	1025	0.3	2.3	100	68	100	77.4


Characteristics		Range

No. of patients	1085

Age, mean (SD)	44.72(12.12)	13-82

No. of women (%)	846(77.97%)

Educational degree	Primary school	85

	Junior high	60

	Senior high	211

	College	576

	Post-graduate	153

Characteristics

No. of patients

Age, mean (SD)

No. of women (%)

Educational degree

	Range

1085

44.72(12.12)	13-82

846(77.97%)

Primary school	85

Junior high	60

Senior high	211

College	576

Post-graduate	153


	N	Mean ± SD	Median	IQR	Range	β ± SE (p)

a)	Persisted to 2nd year	23	0·110 ± 0·068	0·105	0·061–0·139	0·026–0·308	2·9 ± 3·7 (0·44)


	Mean (mm)	Standard Deviation (mm)

Study I	0.43	3.54

Study II	‐1.77	5.23


Variable	Event	PYs	Rate	Crude HR (95% CI)	Adjusted HR (95% CI)


Cox regression	Crude analysis	Adjusted analysis

Variable	RR	95% CI	RR	95% CI

Sex

 Female	1		1

 Male	1.48	0.80-2.74	1.50	0.81-2.79

Age	1.03*	1.01-1.05	1.03*	1.01-1.05

Suicide prevention team

 No	1		1

 Yes	0.76	0.41-1.39	0.85	0.46-1.57

Previous attempt

 No	1

 One	1.56	0.72-3.39

 Several	0.93	0.47-3.95

Aftercare referrals

 Others	1		1

 Out-patient	0.72	0.38-1.35	0.88	0.64-1.21

Alcohol misuse

 No	1

 Yes	1.07	0.51-2.23

Marital status

 Others	1

 Married/cohabitant	1.28	0.67-2.48

Employment

 Employed	1

 Unemployed/disabled	1.48	0.57-3.81

 Student/pupil	0.57	0.16-2.05

 Others	2.82*	1.19-6.66

Cox regression	Crude analysis	Adjusted analysis

Variable	RR	95% CI	RR

Sex

Female	1		1

Male	1.48	0.80-2.74	1.50

Age	1.03*	1.01-1.05	1.03*

Suicide prevention team

No	1		1

Yes	0.76	0.41-1.39	0.85

Previous attempt

No	1

One	1.56	0.72-3.39

Several	0.93	0.47-3.95

Aftercare referrals

Others	1		1

Out-patient	0.72	0.38-1.35	0.88

Alcohol misuse

No	1

Yes	1.07	0.51-2.23

Marital status

Others	1

Married/cohabitant	1.28	0.67-2.48

Employment

Employed	1

Unemployed/disabled	1.48	0.57-3.81

Student/pupil	0.57	0.16-2.05

Others	2.82*	1.19-6.66


<underline>TOP10 with pLC-T4LysHeat</underline>

Lysis entity in exponential phase [%]	73 ± 0.3

Lysis delay after induction [min]	55

Doubling time [min]	66.1 ± 1.7

Doubling time of negative control [min]	65.9 ± 0.6


Gene	Primer sequence

Collagen II	Forward primer 5′‐GCTCCCAGAACATCACCTACCA‐3′Reverse primer 5′‐ACAGTCTTGCCCCACTTACCG‐3′

Aggrecan	Forward primer 5′‐AGGTCGTGGTGAAAGGTGTTGTG‐3′Reverse primer 5′‐TGGTGGAAGCCATCCTCGTAG‐3′

Sox‐9	Forward primer 5′‐CGAGCCGGACCTCAAGAAG‐3′Reverse primer 5′‐ GCACCAGCGTCCAGTCGTA‐3′

Collagen X	Forward primer 5′‐GCCCTTCTGCTGCTAGTGTCTTT‐3′Reverse primer 5′‐TGTGTCTTGGTGTTGGGTTGTG‐3′

GAPDH	Forward primer 5′‐AAGGTCGGAGTGAACGGATTTG‐3′Reverse primer 5′‐CGTGGGTGGAATCATACTGGAAC‐3′

Gene	Primer sequence

	‐ GCACCAGCGTCCAGTCGTA‐3′

Collagen X	Forward primer 5′‐GCCCTTCTGCTGCTAGTGTCTTT‐3′Reverse primer 5′‐TGTGTCTTGGTGTTGGGTTGTG‐3′

GAPDH	Forward primer 5′‐AAGGTCGGAGTGAACGGATTTG‐3′Reverse primer 5′‐CGTGGGTGGAATCATACTGGAAC‐3′


Plant species	Degree of inhibition

Andrographis paniculata	+++

Momordica charantia	++

Cymbopogn citratus	+

Ocimum sanctum	+

Citrus limon	-

Pelargonium citrosum	-

Plant species	Degree of inhibition

Pelargonium citrosum	-


HCV Genotype	Modified Multiplex PCR Method (Genotype Specific Primers)	INNO-LiPA HCV II (Line Probe Assay)

	Isolates, No.	Percentage	Isolates, No.	Percentage

1a	1	1.37	1	1.37

1b	1	1.37	1	1.37

3a	3	4.11	3	4.11

4	65	89.04	38	52.05

4a	-	-	2	2.74

4c/4d	-	-	18	24.66

4e	-	-	5	6.85

4h	-	-	4	5.48

Not Genotyped	3	4.11	1	1.37

Total	73	100	73	100

HCV Genotype	Modified Multiplex PCR Method (Genotype Specific Primers)	INNO-LiPA HCV II (Line Probe Assay)

	Isolates, No.	Percentage	Isolates, No.

1a	1	1.37	1

1b	1	1.37	1

3a	3	4.11	3

4	65	89.04	38

4a	-	-	2

4c/4d	-	-	18

4e	-	-	5

4h	-	-	4

Not Genotyped	3	4.11	1

Total	73	100	73


Characteristics	Frequency	Percentage

Sex

 Male	482	53.8

 Female	414	46.2

Religion

 Christianity	888	99.1

 Islam	6	0.7

 Traditional African Religion	2	0.2

Parental Background

 Father dead	80	8.9

 Mother dead	32	3.6

 One or both parents dead	106	11.8

 Parents alive but divorced	23	2.6

 Parents deprivation	129	14.4

 Father smokes	62	6.9

 Mother smokes	3	0.3

 Father takes alcohol	306	34.2

 Mother takes alcohol	130	14.5


Sample	Wild type CHO-S crude protein extract	pcDNA: trp-21-472-cA transfected CHO-S cell crude protein extract

Replicates	1	2	3	1	2	3

0 min	0.203	0.205	0.202	0.205	0.208	0.206


Variable		Men (n = 21)	Women (n = 19)	Total (n = 40)

	Wee	10	96.4 ±


Groups	Dose (TCID50) 1 mL	Survival rate (day post infection)	Mortality (%)

6	7	8	9	10	11	12	13	14

Control	DMEM	4/4	4/4	4/4	4/4	4/4	4/4	4/4	4/4	4/4	0


Supplementary addition of L- proline (mM)	0	1	2	4	8	12

Hyp (g/L)	2.28	2.81	3.25	6.72	5.56	6.32

Supplementary addition of L- proline (mM)	0	1	2	4	8	12

Hyp (g/	2.2	2.8	3	6.	5	6.32


Treatment	Open dentinal tubules (N/mm2) (N=20)	Diameter of tubules (μm) (N=20)

Old root 	Young root 	Old root 	Young root

Citric acid	122 (14) 	152 (19) 	2.0 (0.1) 	1.7 (0.2)

EDTA	161 (22) 	140 (17) 	2.3 (0.1) 	1.7 (0.2) a

Control	147 (10) 	159 (24) 	1.6 (0.2) 	1.9 (0.2)


SOUND CATEGORY	DESCRIPTION

Mouth	Crunching a hard candy

	Kissing

	Gargling

	Crunching chips

	Finishing a beverage with a straw

Hand	Ripping a sheet of paper

	Unrolling scotch tape

	Zipping a zipper

	Opening a soda can

	Crushing a soda can

Environmental	Train passing by

	Howling wind

	Waves breaking on the shore

	Electric discharge

	Water dripping

Hand control (Fuzzy)	Crumple can

	Open can

	Zip

	Scotch

	Paper

Mouth control (Fuzzy)	Kiss

	Candy

	Chips

	Gargle

	Straw


Antigen	Antibody	Crude IRR (95%CI)	P-value	Age-adjusted IRR	P-value

MSP3


	CEER	Reverse Phase Protein Array	PhosphoFlow	ELISA

Sample Protein Requirement	Native proteins	Denatured proteins	Fixed proteins	Native or Fixed proteins

Minimum Cell Requirement (Assay Sensitivity)	1 cell	2500~15000 cells	1 × 104~1 × 106 cells	150 to 300 cells

Multiplex Format	One sample, multiple analytes	Multiple samples, one analyte	One sample, multiple analytes (limited)	Multiple samples, one analyte

Assay Specificity	• High	• Low	• Low	• Medium

Advantages of Assay	• Simultaneous analysis of multiple analytes (e.g. selected analytes of a signaling pathway) on a single sample.• Suitable for clinical samples of rare cells as well as limited solid tissue samples.	• Simultaneous analysis of multiple samples for a single analyte.• Suitable for samples of cells or solid tissue.	• Detection of target molecules within a cell population in one sample.• Suitable for blood sample analysis.	• High throughput.

Disadvantages of Assay	• Screening compatible antibody sets for each target.	• Need to print each sample; not suitable for applications in clinical samples from individual patients.• Cross reaction of detector antibody.	• Not suitable for rare cell analysis or solid tissue samples.• Requires a large number of cells.• Requires samples in single cell suspension, limiting its use.	• Low sensitivity requires large numbers of cells.• Not suitable for rare cell analysis.


	Sensitivity	Specificity	Positive Predictive Value	Negative Predictive Value

PF/other1(PF gametocytaemia considered negative for PF)	89.1[85.5-91.8]	97.6[96.5-98.4]	93.8[90.8-95.9]	95.2[94.2-96.8]

PF/other2(PF gametocytaemia considered positive for PF)	85.1[81.3-88.2]	96.1[94.7-97.2]	90.6[87.3-93.2]	93.6[91.9-95.0]

PF mono-infection1(PF gametocytaemia considered negative for PF)	95.6[87.7-98.5]	-	-	-

PF mono-infection2(PF gametocytaemia considered positive for PF)	86.7[79.9-91.4]	-	-	-

PV mono-infection1(PV gametocytaemia considered negative for PV)	91.0[86.5-94.1]	-	-	-

PV mono-infection2(PV gametocytaemia considered positive for PV)	88.4[83.7-91.9]	-	-	-


ORF	Gene	Identification	Genotype used in this study

F17A2.5	ceh-40	Homeodomain protein (Extradenticle ortholog)	ceh-40(ok740) X

K10B4.6	cwn-1	Putative Wnt ligand	cwn-1(ok546) II

D1081.2	unc-120	MADS domain TF	unc-120(st364) I

B0304.1	hlh-1	bHLH TF	hlh-1(cc561) II

C44C10.8	hnd-1	Hand bHLH TF	hnd-1(q740) X

F35G12.6	mab-21	Highly conserved novel protein	mab-21(bx53)III; him-5(e1490)V

F11C1.6	nhr-25	Nuclear hormone receptor	+/szT1 [lon-2(e678)] I; nhr-25(jm2389)/szT1 X

Y75B8A.2	nob-1	Homeodomain TF (posterior Hox paralog)	nob-1(ct223) dpy-18(e364) unc-25(e156) III; eDp6 (III;f)

K02B9.4	elt-3	GATA TF	elt-3(gk121) X

T07C4.2	tbx-8	T-box TF (Brachyury)	tbx-8(ok656) III

M142.4	vab-7	Homeobox TF (even-skipped subfamily)	vab-7(e1562) III

T07C4.6	tbx-9	T-box TF (Brachyury)	Mutant not available

C55C2.1		Zinc-finger TF	Mutant not available

C38D4.6	pal-1	Homeobox TF (cad subfamily)	pal-1(ct224) dpy-17(e164) ncl-1(e1865) unc-36(e251) III; sDp3(f:III); lin-2(e1309) X

W09C2.1	elt-1	GATA TF	elt-1(zu180) unc-43(e408)/unc-24(e138) dpy-20(e1282) IV

F18A1.2	lin-26	Zinc-finger TF	lin-26(n156) II

T28F12.2	unc-62	Meis-class homeodomain (Homothorax ortholog)	unc-62(e644) V

C28C12.7	spp-10	Predicted prosaposin	Mutant not available

R02D3.1		Dehydrogenase	Mutant not available

C09D4.2		Uncharacterized	Mutant not available

R07C3.11		Uncharacterized	Mutant not available

T22B7.3		Uncharacterized	Mutant not available

C46H11.2		Uncharacterized	Mutant not available

ZK1307.1		Uncharacterized	Mutant not available

C01G6.1	aqp-2	Aquaporin	Mutant not available

T27D12.1		Sodium/phosphate transporter	Mutant not available

ORF	Gene	Identification

F17A2.5	ceh-40	Homeodomain protein (Extradenticle ortholog)

K10B4.6	cwn-1	Putative Wnt ligand

D1081.2	unc-120	MADS domain TF

B0304.1	hlh-1	bHLH TF

C44C10.8	hnd-1	Hand bHLH TF

F35G12.6	mab-21	Highly conserved novel protein

F11C1.6	nhr-25	Nuclear hormone receptor

Y75B8A.2	nob-1	Homeodomain TF (posterior Hox paralog)

K02B9.4	elt-3	GATA TF

T07C4.2	tbx-8	T-box TF (Brachyury)

M142.4	vab-7	Homeobox TF (even-skipped subfamily)

T07C4.6	tbx-9	T-box TF (Brachyury)

C55C2.1		Zinc-finger TF

C38D4.6	pal-1	Homeobox TF (cad subfamily)

W09C2.1	elt-1	GATA TF

F18A1.2	lin-26	Zinc-finger TF

T28F12.2	unc-62	Meis-class homeodomain (Homothorax ortholog)

C28C12.7	spp-10	Predicted prosaposin

R02D3.1		Dehydrogenase

C09D4.2		Uncharacterized

R07C3.11		Uncharacterized

T22B7.3		Uncharacterized

C46H11.2		Uncharacterized

ZK1307.1		Uncharacterized

C01G6.1	aqp-2	Aquaporin

T27D12.1		Sodium/phosphate transporter

Genotype used in this study

ceh-40(ok740) X

cwn-1(ok546) II

unc-120(st364) I

hlh-1(cc561) II

hnd-1(q740) X

mab-21(bx53)III; him-5(e1490)V

+/szT1 [lon-2(e678)] I; nhr-25(jm2389)/szT1 X

nob-1(ct223) dpy-18(e364) unc-25(e156) III; eDp6 (III;f)

elt-3(gk121) X

tbx-8(ok656) III

vab-7(e1562) III

Mutant not available

Mutant not available

pal-1(ct224) dpy-17(e164) ncl-1(e1865) unc-36(e251) III; sDp3(f:III); lin-2(e1309) X

elt-1(zu180) unc-43(e408)/unc-24(e138) dpy-20(e1282) IV

lin-26(n156) II

unc-62(e644) V

Mutant not available

Mutant not available

Mutant not available

Mutant not available

Mutant not available

Mutant not available

Mutant not available

Mutant not available

Mutant not available


Variables	R	p-Value **

Socioeconomic

Age (years)	0.125	0.243

Schooling (years)	0.118	0.267

Per capita income (real)	−0.080	0.441

Water supply	0.061	0.565

Garbage collection	0.008	0.935

Sewer connect to the public network or existence of septic tank	0.162	0.128

Basic sanitation	0.226	0.033

Obstetric

Parity (number of pregnancies)	−0.125	0.243

Trimester at the time of blood collection	−0.317	0.002

Nutritional

Pre-gestational nutritional status (BMI/age) *	0.276	0.008

Gestational nutritional status (BMI) *	0.246	0.019

Infection (CRP ≥ 5 mg/L)	−0.068	0.527

Nutrient intake

Vitamin A (μg) *	0.046	0.666

Zinc (mg) *	0.048	0.654

Iron (mg) *	0.001	0.986

Variables	R	p-Value **

Garbage collection	0.008	0.935

Sewer connect to the public network or existence of septic tank	0.162	0.128

Basic sanitation	0.226	0.033

Obstetric

Parity (number of pregnancies)	−0.125	0.243

Trimester at the time of blood collection	−0.317	0.002

Nutritional

Pre-gestational nutritional status (BMI/age) *	0.276	0.008

Gestational nutritional status (BMI) *	0.246	0.019

Infection (CRP ≥ 5 mg/L)	−0.068	0.527

Nutrient intake

Vitamin A (μg) *	0.046	0.666

Zinc (mg) *	0.048	0.654

Iron (mg) *	0.001	0.986


Summary of progress with IRS and ITNs	MIS 2006	MIS 2008	MIS 2010

Percentage of households receiving indoor residual spraying (IRS) in the previous 12 months among all households	9.5	14.9	23.1

Percentage of household members who slept under an ITN the previous night	19	34	42

Percentage of households covered by at least one ITN or recent IRS	43.2	68.3	72.9

Percentage of households covered by at least one ITN or recent IRS	43	68	73

Percentage of children ages 0–59 months who slept under an ITN the previous night	24	41	50

Percentage of children ages 0–59 months with malaria parasitaemia	22	10	16

Summary of progress with IRS and ITNs	MIS 2006	MIS 2008	MIS 2010

Percentage of children ages 0–59 months who slept under an ITN the previous night	24	41	50

Percentage of children ages 0–59 months with malaria parasitaemia	22	10	16


	Factors

Self-assessment item	1	2	3

1) Obtain a medical history that is relevant to the patient's complaint	0.83

2) Perform a clinical examination that is targeted at the patient's chief complaint	0.72		0.39

3) Obtain a psychosocial history from the patient	0.67	0.33

4) Announce bad news (e.g., an unfavorable prognosis)	0.61	0.32

5) Make sure that an illiterate patient understands the treatment of his chronic disease (e.g., hypertension, depression, etc.)	0.52	0.43

6) Explain the reason for refusing an unjustified treatment or investigation to patient who requests it	0.52

7) Discuss advantages and risks of unconventional therapies with a patient who uses them		0.48

8) Discuss a patient's religious preferences and constraints regarding his treatment		0.73

9) Communicate the importance of medical treatment to a patient who believes that his illness is due to supernatural causes		0.65

10) Explore the migratory trajectory and possible traumatic experiences of an asylum seeker		0.68

11) Work effectively with a professional interpreter			0.65

12) Orient an immigrant patient without papers toward appropriate medical and social services		0.47	0.41

13) Perform a physical examination of a Muslim woman who wears a veil			0.79

14) Ask questions and give information to the husband of a patient, if she requests it			0.76

	Factors

8) Discuss a patient's religious preferences and constraints regarding his treatment		0.73

9) Communicate the importance of medical treatment to a patient who believes that his illness is due to supernatural causes		0.65

10) Explore the migratory trajectory and possible traumatic experiences of an asylum seeker		0.68

11) Work effectively with a professional interpreter			0.65

12) Orient an immigrant patient without papers toward appropriate medical and social services		0.47	0.41

13) Perform a physical examination of a Muslim woman who wears a veil			0.79

14) Ask questions and give information to the husband of a patient, if she requests it			0.76


Group	nNOS activity (nmol/min/mg)	MDA nmol/g/wet tissue	GSH nmol/g/wet tissue

Control	0.604 ± 0.04	3.55 ± 0.20	1.68 ± 0.15

Cocaine	0.935 ± 0.14*	4.65 ± 0.32*	0.94 ± 0.10*

7-N		3.50 ± 0.10	1.59 ± 0.1


Parameters	Base-case	Range (min—max)	Reference

Thai birth cohort population	782,129	–	(19)

Incidence of haemophilus influenzae type b (Hib) meningitis in <1 year old	0.000137	0.000038–0.000236	(14, 20)

Incidence of Hib meningitis in ≥1 to <5 years olda	0.000046	0.000038–0.000054

Incidence of Hib pneumonia in <5 years	0.000959	0.000266–0.001652	(21)b

Incidence of Hib NPNM in population <5 years old	0.000025	0.000007–0.000043	(1)c

Case-fatality ratio of Hib meningitis

Estimate based on real-world evidence of national database (base-case analysis)	0.029	0.018–0.040	NHSOd

Estimate from published article	0.099	0.049–0.149	(22)

Case-fatality ratio of Hib pneumonia

Estimate based on real-world evidence of national database (base-case analysis)	0.019	0.012–0.026	NHSOd

Estimate from published article	0.020	0.010–0.030	(1)

Case-fatality ratio of Hib NPNM

Estimate based on real-world evidence of national database (base-case analysis)	0.050	0.022–0.078	NHSOd

Estimate from published article	0.010	0.005–0.015	(1)

Probability of hearing loss after recovery from Hib meningitis	0.111	0.055–0.167

Probability of epilepsy after recovery from Hib meningitis	0.050	0.025–0.075	(23)

Probability of developmental deficit after recovery from Hib meningitis	0.083	0.041–0.125

Risk ratio of mortality compared to general population

Hearing loss	1.075	1.010–1.140

Epilepsy	1.005	1.000–1.010	(24)

Developmental deficit	6.165	5.160–7.170

Parameters	Base-case	Range (min—max)	Reference

Epilepsy	1.005	1.000–1.010	(24)

Developmental deficit	6.165	5.160–7.170


Clinical features	FA	XP	CS	TTD

Cancer	+	+	-	-

Skin pigmentation	+	+	-	±

Developmental delay	+	-	+	+

Neurological defects	±	±	+	+

Clinical features	FA	XP	CS	TTD

Skin pigmentation	+	+	-	±

Developmental delay	+	-	+	+

Neurological defects	±	±	+	+


Operational Mode	bits/s	kbits/sol	Power(mW)	Energy/sol(mWh)

Nominal (1sps during 5 min each hour)	112	806.4	0.25	0.5

In-flight calibration (1sps during 15 min each week)	112	14.4	500	17.8

Total	-	820.8	-	18.3


Surgery Type (# of Patients) Ref.	Prognostic Value (Y/N/Insignificant)	Remarks

General/vascular surgery (143)39	Insignificant	Suggested conducting randomized control trial

Spine (268)40	Yes

General orthopedic (723)41	No	SAS did not predict 30-day major complications after general orthopedic surgery

Radical cystectomy (155)42	Yes

General surgery (2,125)43	Yes

Laparotomy (218)44	Yes

Non-cardiac surgeries (5,909)45	Yes

General and vascular surgeries (224)46	Yes

General, vascular, and orthopedic surgeries (223)47	Yes	SAS uncorrelated with orthopedic patients who had major events

Renal mass excision (886)48	Yes

High-risk intra-abdominal surgeries (355)49	Yes	SAS was significantly predictive but weakly discriminative for adverse events

Surgery Type (# of Patients) Ref.	Prognostic Value (Y/N/Insignificant)	Remarks

General/vascular surgery (143)39	Insignificant	Suggested conducting randomized control trial

Spine (268)40	Yes

General orthopedic (723)41	N	S

Surgery Type (# of Patients) Ref.	Prognostic Value (Y/N/Insignificant)	Remarks

	o	AS did not predict 30-day major complications after general orthopedic surgery

Radical cystectomy (155)42	Yes

General surgery (2,125)43	Yes

Laparotomy (218)44	Yes

Non-cardiac surgeries (5,909)45	Yes

General and vascular surgeries (224)46	Yes

General, vascular, and orthopedic surgeries (223)47	Yes	SAS uncorrelated with orthopedic patients who had major events

Renal mass excision (886)48	Yes

High-risk intra-abdominal surgeries (355)49	Yes	SAS was significantly predictive but weakly discriminative for adverse events


Asset index items	Scoring factors	% of distribution in the sample	Most poor (%)	Least poor (%)

Refrigerator	0.382	48.4	0	100

Radio	0.231	65.8	41.1	91

Television	0.368	47.5	0	40

Stove	0.357	59.2	0	98

Phone	0.329	43.7	0	40

Car	0.161	7.3	0	21

Drinking water(Piped inside the house)	0.379	45.4	0	55

Type of toilet( Flush toilet)	0.358	48.2	0	41

Cooking fuel(Using electricity for cooking)	0.36	35.4	0	43

Asset index items	Scoring factors	% of distribution in the sample	Most poor (%)	Least poor (%)

Television	0.368	47.5	0	40

Stove	0.357	59.2	0	98

Phone	0.329	43.7	0	40

Car	0.161	7.3	0	21

Drinking water(Piped inside the house)	0.379	45.4	0	55

Type of toilet( Flush toilet)	0.358	48.2	0	41

Cooking fuel(Using electricity for cooking)	0.36	35.4	0	43


Molecular function term	% Coverage	p-value	FDR (%)

catalytic activity	43	1.32E-04	0.22

nucleotide binding	14	1.27E-05	0.02

purine nucleotide binding	13	4.74E-05	0.08

purine ribonucleotide binding	12	1.49E-05	0.02

ribonucleotide binding	12	1.49E-05	0.02

RNA binding	11	1.60E-09	2.71E-06

structural molecule activity	10	4.34E-12	7.36E-09

structural constituentof ribosome	9	4.38E-22	7.43E-19

GTP binding	3	7.43E-06	0.01

guanyl nucleotide binding	3	7.43E-06	0.01

guanyl ribonucleotide binding	3	7.43E-06	0.01

oxidoreductase activity, acting on CH-OH group of donors	3	4.66E-05	0.08

translation regulator activity	3	8.71E-07	1.48E-03

oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor	3	1.10E-04	0.19

translation factor activity, nucleic acid	3	2.14E-07	3.62E-04

GTPase activity	2	2.39E-03	3.98

rRNA binding	2	8.85E-11	1.50E-07

snoRNA binding	2	8.58E-09	1.45E-05

ligase activity, forming aminoacyl-tRNA and related compounds	2	1.33E-06	2.25E-03

ligase activity, forming carbon- oxygen bonds	2	1.33E-06	2.25E-03

aminoacyl-tRNA ligase activity	2	1.33E-06	2.25E-03

RNA helicase activity	2	4.29E-05	0.07

ATP-dependent RNA Helicase activity	2	9.12E-07	1.54E-03

RNA-dependent ATPase activity	2	9.12E-07	1.54E-03

translation initiation factor activity	1	4.61E-04	0.78


	No. of pts.	Spearmen-Rho	p-value

Quality of life

Health status	111	0.882	0.000

ICIQ (1)	111	−0.211	0.027

IPSS (2)	104	−0.204	0.037

Urethral D30 (3)

Volume of prostate	162	−0.326	0.000

IPSS at survey

IPSS (preimplant)	103	0.287	0.003

Seed dislocation/loss

V100 (4)	163	−0.262	0.001

D90 (5)	163	−0.190	0.015

	No. of pts.	Spearmen-Rho	p-value

t survey

IPSS (preimplant)	103	0.287	0.003

Seed dislocation/loss

V100 (4)	163	−0.262	0.001

D90 (5)	163	−0.190	0.015


INTAKE24 Geometric Mean	Interview Geometric Mean	Ratio of Geometric Mean	Limits of Agreement


Wheat in OSR (in 2000)	Infectivity of Soil (% roots)a	Take-All in Spring	Take-All in Summer	Take-All Index (0–100)	Grain Yield (t ha−1)

Total(% plants)	No. Roots(plant−1)	Total (% plants)	Mod. (% plants)b

None	−2.55 (0.1)	−1.56 (3.8)	0.07	−1.73 (2.5)	−2.44 (0.3)	1.0	8.20

Destroyed early	−2.78 (0.0)	−1.81 (2.1)	0.06	−1.75 (2.4)	−2.24 (0.6)	1.7	8.56


Organism	Release version	Coverage depth	Genome size (Mbp)	Scaffolds numbers	EST Size (Mbp)	EST numbers

Aq	v1.0	~8X	143	3,579	42	63,542

Ta	v1.0	~8.1X	107	1,415	8	11,498


System	Manifestation

Digestive system	Burning throat, nausea, vomiting, abdominal pain, abdominal distension

Nervous system	Dizziness, vertigo, dysarthria, dysphagia, blurred vision, diplopia, drooping eyelids, mydriasis, miosis, absence of pupillary light reflex, gait ataxia, fatigue, convulsion, numbness, restlessness, loss of consciousness

Respiratory system	Chest tightness, tachypnea, bradypnea, shortness of breath, irregular breathing, respiratory arrest, cyanosis

Circulatory system	Palpitation, bradycardia, tachycardia, cardiac arrest, decrease of blood pressure

System	Manifestation

Digestive system	Burning throat, nausea, vomiting, abdominal pain, abdominal distension

	Dizziness, vertigo, dysarthria, dysphagia, blurred vision, diplopia, drooping eyelids, mydriasis, miosis, absence of pupillary light reflex, gait atax

System	Manifestation

Nervous system	ia, fatigue, convulsion, numbness, restlessness, loss of consciousness

Respiratory system	Chest tightness, tachypnea, bradypnea, shortness of breath, irregular breathing, respiratory arrest, cyanosis

Circulatory system	Palpitation, bradycardia, tachycardia, cardiac arrest, decrease of blood pressure


Entry Plasmidsa	Applications

pL1R5-BGHpA-empty	1. The TALEN Entry plasmid pairs can be used for

pL1R5-CAG-EGFP-T2A-TALEN-NN-BGHpA	 TALEN functional tests.

pL1R5-CAG-EGFP-T2A-TALEN-NI-BGHpA	2. The TALEN Entry plasmids contain EGFP or

pL1R5-CAG-EGFP-T2A-TALEN-NG-BGHpA	mCherry reporters, which can be used for

pL1R5-CAG-EGFP-T2A-TALEN-HD-BGHpA	monitoring transfection efficiency and cell sorting.

	3. Through LR recombination, the TALEN pairs can

pL5L2-empty	be transferred to pPB-DEST or pPB-Puro-DEST or

pL5L2-EF1α-mCherry-T2A-TALEN-NN	other destination vectors.

pL5L2-EF1α-mCherry-T2A-TALEN-NI	4. TALENs in pL1R5-BGHpA vectors together with

pL5L2-EF1α-mCherry-T2A-TALEN-NG	pL5L2 empty vector can be recombined into

pL5L2-EF1α-mCherry-T2A-TALEN-HD	pAd/PL-DEST to produce adenoviruses with CAG

	EGFP. Alternatively the reverse insertion of

pL5L2-CAG-mCherry-T2A-TALEN-NN	TALENs in pL5L2 vectors together with pL1R5 -

pL5L2-CAG-mCherry-T2A-TALEN-NI	BGHpA empty vector can be recombined into

pL5L2-CAG-mCherry-T2A-TALEN-NG	pAd/PL-DEST to produce adenoviruses with EF1α

pL5L2-CAG-mCherry-T2A-TALEN-HD	mCherry or CAG-mCherry.

Entry Plasmidsa	Applications

pL1R5-BGHpA-empty

pL1R5-CAG-EGFP-T2A-TALEN-NN-BGHpA

pL1R5-CAG-EGFP-T2A-TALEN-NI-BGHpA

pL1R5-CAG-EGFP-T2A-TALEN-NG-BGHpA

pL1R5-CAG-EGFP-T2A-TALEN-HD-BGHpA

pL5L2-empty

pL5L2-EF1α-mCherry-T2A-TALEN-NN

pL5L2-EF1α-mCherry-T2A-TALEN-NI

pL5L2-EF1α-mCherry-T2A-TALEN-NG

pL5L2-EF1α-mCherry-T2A-TALEN-HD

pL5L2-CAG-mCherry-T2A-TALEN-NN

pL5L2-CAG-mCherry-T2A-TALEN-NI

pL5L2-CAG-mCherry-T2A-TALEN-NG

pL5L2-CAG-mCherry-T2A-TALEN-HD

Applications

1. The TALEN Entry plasmid pairs can be used for

TALEN functional tests.

2. The TALEN Entry plasmids contain EGFP or

mCherry reporters, which can be used for

monitoring transfection efficiency and cell sorting.

3. Through LR recombination, the TALEN pairs can

be transferred to pPB-DEST or pPB-Puro-DEST or

other destination vectors.

4. TALENs in pL1R5-BGHpA vectors together with

pL5L2 empty vector can be recombined into

pAd/PL-DEST to produce adenoviruses with CAG

EGFP. Alternatively the reverse insertion of

TALENs in pL5L2 vectors together with pL1R5 -

BGHpA empty vector can be recombined into

pAd/PL-DEST to produce adenoviruses with EF1α

mCherry or CAG-mCherry.


Gene	Primers	Sequence

PRP8	Forward	TCATGGCTGCGTCTGAAGTA

Reverse	GGCTCAAACCCTTCCGATAG

MET18	Forward	TGCTGGAAGTTGTCGTTGC

Reverse	TCGTTTTTGGAGAGGTGGTC

CTT1	Forward	GATTCCGTTCTACAAGCCAGAC

Reverse	GGAGTATGGACATCCCAAGTTTC

CTA1	Forward	CCAACAGGACAGACCCATTC

Reverse	TTACCCAAAACGCGGTAGAG


Species	# of Strains	Genome size (Mb)	GC content (%)

Fungi (Kingdom)

 Ascomycota (Phylum)

Pezizomycotina (Subphylum)

Aspergillus fumigatus	2	29.3 ± 0.1	49.672 ± 0.178

Aspergillus niger	2	35.6 ± 2.3	50.365 ± 0.012

Coccidioides immitis	4	28.3 ± 0.7	46.529 ± 0.514

Coccidioides posadasii	11	27.2 ± 0.9	46.839 ± 0.537

Histoplasma capsulatum	5	36.2 ± 4.7	43.400 ± 1.859

Paracoccidioides brasiliensis	3	30.7 ± 2.0	43.868 ± 0.930

Fusarium graminearuma	2	36.6	48.283

Saccharomycotina (Subphylum)

Candida albicans	2	14.4 ± 0.1	33.462 ± 0.010

Saccharomyces cerevisiae	3	11.9 ± 0.3	38.252 ± 0.090

Saccharomyces bayanus	2	11.7 ± 0.3	40.196 ± 0.011

Saccharomyces mikataeb	2	11.1 ± 0.5	37.920 ± 0.315

Basidiomycota (Phylum)

Agricomycotina (Subphylum)

Cryptococcus neoformans	4	19.2 ± 0.2	48.251 ± 0.316

Ustilaginomycotina (Subphylum)

Ustilago maydis	2	19.7 ± 0.0	53.995 ± 0.045

Chytridiomycota (Phylum)

Batrachochytrium dendrobatidis	2	24.1 ± 0.3	39.261 ± 0.011

Chloroplastida (Kingdom)

 Charophyta (Phylum)

Oryza sativa	2	399.2 ± 38.4	43.530 ± 0.046

Vertebrata (Phylum)

 Vertebrata (Phylum)

Homo sapiens	4	3,052.2 ± 409.3	40.878 ± 0.042


Complication	Evisceration Incidence/%	Enucleation Incidence/%	P value (Fisher’s exact test)

No complication	30/71.4	16/61.5	0.43

Wound dehiscence	4/9.5	3/11.5	1.00

Implant exposure	2/4.8	1/3.8	1.00

Implant extrusion	1/2.4	2/7.7	0.55

Implant migration	0/0	1/3.8	0.38

Infection	2/4.8	1/3.8	1.00

Deep superior sulcus	3/7.1	2/7.7	1.00

Total	42/100	26/100

Complication	Evisceration Incidence/%

No complication	30/71.4

Wound dehiscence	4/9.5

Implant exposure	2/4.8

Implant extrusion	1/2.4

Implant migration	0/0

Infection	2/4.8

Deep superior sulcus	3/7.1

Total	42/100


Epigenetic Process	Target	Function

DNA Methylation	DNA in cell or viral epigenome	Typically silence genes

Nucleosome Location	Cellular and Viral Chromatin	Nucleosome position controls access to DNA sequences

Histone Modification	Cellular and Viral Chromatin	Histone acetylation and methylation on H3K4/H3K36 association with activation of transcription, methylation on H3K9 and H3K27 is associated with repression, methylation of H4K20 could result in either activation or repression

Histone Variants	Cellular and Viral Chromatin	Not yet well understood for viruses

miRNA	Cellular and Viral Chromatin	Modify gene expression at the level of translation

Epigenetic Process	Target

DNA Methylation	DNA in cell or viral epigenome

Nucleosome Location	Cellular and Viral Chromatin

Histone Modification	Cellular and Viral Chromatin

Histone Variants	Cellular and Viral Chromatin

miRNA	Cellular and Viral Chromatin

Function

Typically silence genes

Nucleosome position controls access to DNA sequences

Histone acetylation and methylation on H3K4/H3K36 association with activation of transcription, methylation on H3K9 and H3K27 is associated with repression, methylation of H4K20 could result in either activation or repression

Not yet well understood for viruses

Modify gene expression at the level of translation


Chromosomes	% Aneuploidy (loss, gain)

	Healthy bra	AT		S


Different techniques	NESP for single pulse	Ave. NESP for orthogonal pulses

Seventh derivative Gaussian pulse [35]	46%	-

Hermite Gaussian Functions [20]	65%	65%

PM algorithm [10]	72.41%	-

SOCP based FIR filter [14]	79%	77.5%

SOCP based FIR filter [13]	92.16%	59.26%

Proposed UWB pulse	98.7%	98.7%

Different techniques	NESP for single pulse

Seventh derivative Gaussian pulse [35]	46%

Hermite Gaussian Functions [20]	65%

PM algorithm [10]	72.41%

SOCP based FIR filter [14]	79%

SOCP based FIR filter [13]	92.16%

Proposed UWB pulse	98.7%

Ave. NESP for orthogonal pulses

-

65%

-

77.5%

59.26%

98.7%


	KPs	Aqueous cells	Aqueous flare	Vitreous cells

Pa			3			3	0	1	3	0


Placing State	Other Experiment Settings

Static	Running the whole ARS

Static	Only running Sensors

Static	Running the ARS without activity recognition and result processing

Static	Running the ARS without result processing

Static	The phone on standby

Shaker	Running the whole ARS

Shaker	Only running Sensors

Shaker	Running the ARS without activity recognition and result processing

Shaker	Running the ARS without result processing

Shaker	The phone on standby


Method	1	2	3	4	5	6	7	8	9

A.RANKING ORDER UNDER ALL STRESS(BETTER-GOOD-AVERAGE)

 geNorm	MAP/UBC		FHP	EF 1-α	CGS1	PPK	ATPase	eif4A	DPE2

 NormFinder	UBC	MAP	EF 1-α	FHP	CGS1	PPK	eif4A	ATPase	DPE2

 BestKeeper	MAP	UBC	FHP	PPK	CGS1	EF 1-α	ATPase	eif4A	DPE2

 Δct method	UBC	MAP	FHP	EF 1-α	CGS1	ATPase	eif4A	PPK	DPE2

 Comprehensive ranking	UBC	MAP	FHP	EF 1-α	CGS1	PPK	ATPase	eif4A	DPE2

B.RANKING ORDER UNDER DEHYDRATION STRESS (BETTER-GOOD-AVERAGE)

 geNorm	CGS1/FHP		PPK	UBC	MAP	EF 1-α	eif4A	DPE2	ATPase

 NormFinder	UBC	CGS1	FHP	MAP	EF 1-α	PPK	eif4A	DPE2	ATPase

 BestKeeper	CGS1	FHP	PPK	UBC	MAP	EF 1-α	DPE2	ATPase	eif4A

 Δct method	UBC	CGS1	FHP	MAP	PPK	EF 1-α	eif4A	ATPase	DPE2

 Comprehensive ranking	CGS1	UBC	FHP	PPK	MAP	EF 1-α	eif4A	DPE2	ATPase

C.RANKING ORDER UNDER TEMPERATURE STRESS (BETTER-GOOD-AVERAGE)

 geNorm	MAP/ATPase		EF 1-α	UBC	CGS1	FHP	PPK	DPE2	eif4A

 NormFinder	UBC	MAP	CGS1	EF 1-α	ATPase	FHP	DPE2	PPK	eif4A

 BestKeeper	MAP	ATPase	UBC	CGS1	PPK	EF 1-α	FHP	DPE2	eif4A

 Δct method	UBC	MAP	ATPase	EF 1-α	CGS1	FHP	DPE2	PPK	eif4A

 Comprehensive ranking	MAP	UBC	CGS1	ATPase	EF 1-α	FHP	PPK	DPE2	eif4A


System	Effect	Manifestation

Renal	Renal vein compression, cortical arteriolar compression	Oliguria, rising creatinine

Pulmonary	Upward pressure on diaphragm, decreased compliance and functional residual capacity, increased air way resistance	Hypoxia, hypercarbia, elevated airway pressure, decreased tidal volume

Cardiovascular	Decreased venous return, increased afterload	Decreased cardiac output

Cerebral	Increased intrathoracic pressure with decreased cerebral venous outflow	Elevated Intra Cranial Pressure

Splanchnic	Decreased perfusion of liver and intestine	Metabolic acidosis, bowel ischemia

System	Effect

Renal	Renal vein compression, cortical arteriolar compression

Pulmonary	Upward pressure on diaphragm, decreased compliance and functional residual capacity, increased air way resistance

Cardiovascular	Decreased venous return, increased afterload

Cerebral	Increased intrathoracic pressure with decreased cerebral venous outflow

Splanchnic	Decreased perfusion of liver and intestine

Manifestation

Oliguria, rising creatinine

Hypoxia, hypercarbia, elevated airway pressure, decreased tidal volume

Decreased cardiac output

Elevated Intra Cranial Pressure

Metabolic acidosis, bowel ischemia


	Ever Delirium (n = 125)	Never Delirium (n = 135)	p-value

Characteristic

 Mean age (± 1 SD; years)	56 (± 18)	49 (± 17)	0.002

 Male	62 (50%)	67 (50%)	1.0

 No. of Caucasians	99 (79%)	115 (85%)	0.25

 APACHE II score, median (IQR)	15 (10–21)	11 (6–16)	<0.001

 Charlson co-morbidity index, median (IQR)	4 (2–7)	3 (1–6)	0.079

Diagnostic category for ICU admission (%)b

 Pulmonary	29	40

 Gastrointestinal	20	21

 Metabolic	22	18

 Cardiac	7	9

 Hematology/oncology	5	4

 Neurologic	5	3

 Renal	9	2

 Other	3	3

	Ever Delirium (n = 125)	Never Delirium (n = 135)	p-value

Mean age (± 1 SD; years)	56 (± 18)	49 (± 17)	0.002

Male	62 (50%)	67 (50%)	1.0

No. of Caucasians	99 (79%)	115 (85%)	0.25

APACHE II score, median (IQR)	15 (10–21)	11 (6–16)	<0.001

Charlson co-morbidity index, median (IQR)	4 (2–7)	3 (1–6)	0.079

Diagnostic category for ICU admission (%)b

Pulmonary	29	40

Gastrointestinal	20	21

Metabolic	22	18

Cardiac	7	9

Hematology/oncology	5	4

Neurologic	5	3

Renal	9	2

Other	3	3


	Function-based screening	Sequence-based screening	SIGEX

Screening principle	• Detecting changes by enzymatic reactions (e.g. halo formation around the colonies)	• PCR or Southern hybridization based on the DNA sequence consensus	• Trapping the operon induced by a substrate and sorting using FACS

Advantages	• Secures a complete form of gene or gene cluster required for desired traits• Potentially obtains completely novel genes.	• Overcomes the limitations of the heterologous expression	• Fast and economical• Any substrates that can be introduced into cytoplasm can be used in its native forms.

Disadvantages	• Must satisfy the expression conditions (transcription, translation, folding, secretion) in heterologous hosts	• Requires a database and analyses of the DNA sequence consensus.• Does not guarantee the acquisition of complete forms of genes or gene clusters.	• Sensitive to the orientation of the genes with desired traits• Cannot use substrates that do not migrate to cytoplasm• Sensitive to the initial FACS setting

Examples	antibiotics [9, 19-22], genes involved antibiotic resistance [9, 23, 24], agarases [15], amidases [13], amylases [15, 21, 25, 26], esterase/lipases [8, 15, 21, 27, 28], xylanases [29], 4-hydoxybutyrate dehydrogenase [30] alcohol oxidoreductases [14], pectate lyases [31]	amylases [26], polyketide synthases [32, 33]	Benzoate-degratative or catechol degradative operon, P450 enzyme [16]

	Function-based screening	Sequence-based screening	SIGEX

Examples	antibiotics [9, 19-22], genes involved antibiotic resistance [9, 23, 24], agarases [15], amidases [13], amylases [15, 21, 25, 26], esterase/lipases [8, 15, 21, 27, 28], xylanases [29], 4-hydoxybutyrate dehydrogenase [30] alcohol oxidoreductases [14], pectate lyases [31]	amylases [26], polyketide synthases [32, 33]	Benzoate-degratative or catechol degradative operon, P450 enzyme [16]


Instrument	FAST Year 1	GDS Year 1	CDR-GS Year 1

AQ Year 1	0.84	0.78	0.74

FAQ Year 1	0.83	0.77	0.75

MMSE Year 1	-0.59	-0.64	-0.65

Instrument	FAST Year 1	GDS Year 1

AQ Year 1	0.84	0.78

FAQ Year 1	0.83	0.77

MMSE Year 1	-0.59	-0.64


	odds ratio	95% CI	p-value

Age, years (mean ± SD)	1.01	0.88–1.15	0.920

Education, years (mean ± SD)	1.02	0.88–1.21	0.778


Pathology	Young	AdV	1 mo post DSB	2 mo post DSB	Old

Karyomegaly	1.62±0.38	2.27±0.14	3.00±0*	2.25±0.25	4.00±0**

Intranucle	0	0.09±0.	0.	0.38	3.00


Program

B-TBLASTN

S-TBLASTN

C-TBLASTN


Classifier	Accuracy (%)	Recall rate (%)	F1 measure	Time (s)

EEG	94.2	92.8	93.7	0.01

Skeleton	93.8	93.4	93.8	0.01


Group	Cases, n	In-stent restenosis, n (%)	Angina, n (%)	Myocardial infarction, n (%)	Heart failure, n (%)	Revascularization (unchanged number), n (%)	All-cause mortality, n (%)	MACE events, n (%)	Medical costs, RMB

CR	1020	121 (11.9)	307 (30.1)	18 (1.7)	67 (6.5)	142 (13.9)	12 (1.2)	173 (17)	62,100


Probable

Probable CVID

Male or female patient who has a marked decrease of IgG (at least 2 SD below the mean for age) and a marked decrease in at least one of the isotypes IgM or IgA, and fulfils all of the following criteria:

 ∙ Onset of immunodeficiency at >2 years of age

 ∙ Absent isohemagglutinins and/or poor response to vaccines

 ∙ Defined causes of hypogammaglobulinemia have been excluded

Possible CVID

Male or female patient who has a marked decrease (at least 2 SD below the mean for age) in at least one of the major isotypes (IgM, IgG, and IgA) and fulfils all of the following criteria:

 1. Onset of immunodeficiency at >2 years of age

 2. Absent isohemagglutinins and/or poor response to vaccines

 3. Defined causes of hypogammaglobulinemia have been excluded

Probable

e been excluded

Possible CVID

Male or female patient who has a marked decrease (at least 2 SD below the mean for age) in at least one of the major isotypes (IgM, IgG, and IgA) and fulfils all of the following criteria:

1. Onset of immunodeficiency at >2 years of age

2. Absent isohemagglutinins and/or poor response to vaccines

3. Defined causes of hypogammaglobulinemia have been excluded


Affymetrix ID	FoldΔ	GenBank	Gene	Gene Description

1384944_at	43.3	BE116855	Bcl11b	B-cell leukemia/lymphoma 11B (predicted)

1370041_at	11.7	NM_053440	Stmn2	stathmin-like 2

1378776_at	6.8	BE097103	Pou6f1	POU domain, class 6, transcription factor 1

1368411_a_at	4.6	X74211	Mtap2	microtubule-associated protein 2

1391019_at	3.4	BF285698	Slitrk1	SLIT and NTRK-like family, member 1 (predicted)

1377308_a_at	3.4	BF398408		Neurotrophic tyrosine kinase, receptor, type 3

1368097_a_at	3.4	NM_053865	Rtn1	reticulon 1

1369765_at	3.3	NM_022384	Ascl1	achaete-scute complex homolog-like 1 (Drosophila)

1371618_s_at	3.3	AI229029	Tubb3	tubulin, beta 3

1370043_at	3.3	NM_031753	Alcam	activated leukocyte cell adhesion molecule

1372299_at	3.0	AI013919	Cdkn1c	cyclin-dependent kinase inhibitor 1C (P57)

1368261_at	2.7	NM_053817	Nrxn3	neurexin 3; hypothetical gene supported by NM_053817

1395357_at	2.7	BG672052	Map1b	microtubule-associated protein 1b

1390671_at	2.7	AI044666	Igf1r	Insulin-like growth factor 1 receptor

1373683_at	2.7	AI230396	Fyn	fyn proto-oncogene

1387200_at	2.6	NM_021770	Olig1	oligodendrocyte transcription factor 1

1392477_at	2.6	AI059914	Etv1	ets variant gene 1 (predicted)

1367918_at	2.5	NM_031066	Fez1	fasciculation and elongation protein zeta 1 (zygin I)

1387274_at	2.5	NM_012943	Dlx5	distal-less homeobox 5

1388015_at	2.4	U04998	Ptprz1	protein tyrosine phosphatase, receptor-type, Z polypept. 1

1379693_at	2.4	AI409154	Robo2	Roundabout 2 (Drosophila)

1395986_at	2.3	BF391439	Slit2	slit homolog 2 (Drosophila)

1388419_at	2.3	AW915005		CDK5 regulatory subunit associated protein 2

1369213_at	2.3	NM_017345		neural cell adhesion molecule L1

1379526_at	2.3	BG374506	Mbp	Myelin basic protein

1387424_at	2.2	NM_012884	Cntn2	contactin 2

1370124_at	2.2	NM_053968	Mt3	metallothionein 3

1368148_at	2.2	NM_012610	Ngfr	nerve growth factor receptor (TNFR superfamily, mem 16)

1381215_at	2.2	AA900967		PREDICTED: similar to Numbl protein [Rattus norvegicus]

1368472_at	2.1	NM_031320	Celsr3	cadherin EGF LAG seven-pass G-type receptor 3

1396150_at	2.1	AW917275	Cldn1	claudin 1

1374403_at	2.1	BF412072	Efnb1	ephrin B1

1382205_at	2.1	AW527509		Transcribed locus

1386948_at	2.0	NM_012987	Nes	Nestin

1368879_a_at	2.0	AF413212	Gnao	guanine nucleotide binding protein, alpha o


Variables	Adjusted odds ratio	95 % confidence interval	P

Previous-day aPTTa

≥46 and ≤55 s	2.03	0.68–6.10	0.30

≥56 and ≤69 s	1.32	0.41–4.27	0.47

≥70 s	3.24	1.11–9.44	0.03

Previous-day anticoagulation	0.21	0.06–0.52	<0.01

Daily lowest corporeal temperature	1.79	1.20–2.66	<0.01

APACHE III score	1.03	1.01–1.04	<0.01

Variables	Adjusted odds ratio

Previous-day aPTTa

≥46 and ≤55 s	2.03

≥56 and ≤69 s	1.32

≥70 s	3.24

Previous-day anticoagulation	0.21

Daily lowest corporeal temperature	1.79

APACHE III score	1.03


Protein identification	Accession number (UniProtKB/TrEMBL)	Spot	Fold	Mascot score	Sequence coverage (%)	Peptide number	Molecular mass (kDA)	pI

gSG6 SP	Q9BIH5_ANOGA	794	1.8	14	45.22	14	13.1	5.49

gSG1b SP	Q9BIH6_ANOGA	1197	1.6	59	46.23	59	43.6	7.58

Long form D7 SP	Q7PJ76_ANOGA	1144	1.4	15	40.19	15	35.6	5.90

SG5 SP	Q9BIH7_ANOGA	1228	2.0	15	29.22	15	38.2	6.47

		1229	1.6	14	29.52	14

TRIO protein SP	Q8WR22_ANOGA	819	1.4	12	31.46	12	43.7	6.46

Protein identification	Accession number (UniProtKB/TrEMBL)	Spot	Fold	Mascot score	Sequence coverage (%)	Peptide number	Molecular mass (kDA)	pI

		1228	2.0	21	36.83	21

		1229	1.6	15	29.41	15

		1239	1.4	25	40.15	25


Study and reference	Pack-years of smoking

	Controls (N)	COPDs (N)

Bergen cohort from Pillai et al [26]	19 ± 13*(810)	32 ± 19*(823)

Copenhagen City Heart Study from Kaur-Knudsen et al [25]	NR	NR

COPDGene study from Kim et al [24]	52 ± 29*(335)	37 ± 19*(507)

COPACETIC cohort from Lambrechts et al [23]	38.0 (28.0-46.2) (295)	38.7 (29.7-49.5)(161)

LEUVEN cohort from Lambrechts et al [25]	42.3 (30.0-50.5) (184)	40.0 (30.0-57.0) (475)

NETT/NAS cohorts from Pillai et al [26]	40 ± 28*(472)	66 ± 30*(389)

New Zealand study from Young et al [27]	40 ± 19*(488)	47 ± 20*(458)


Variable category	Characteristics	n (%)

Sex	Male	90 (51.7)

Female	84 (48.3)

Age category	< 30	21 (12.1)

30–60	114 (65.5)

> 60	39 (22.4)

Level of educational	Illiterate	60 (34.5)

Primary education	74 (42.5)

Secondary education	35 (20.1)

College and above	5 (2.9)

Marital status	Single	14 (8.0)

Married	142 (81.6)

Divorced/separated	18 (10.3)

Regular follow up	No	74 (42.5)

Yes	100 (57.5)

Family support	Yes	63 (36.2)

No	111 (63.8)

Duration of diabetes treatment (years)	< 5	53 (30.5)

5–10	35 (20.1)

> 10	86 (49.4)

Co-morbidity	Yes	90 (51.7)

No	84 (48.3)

Type of co-morbidity	Hypertension	71 (78.9)

Ischemic heart disease (IHD)	10 (11.1)

Hypertension + IHD	5 (5.6)

CKD	2 (2.2)

Others	2 (2.2)

Diabetic complications	Yes	71 (40.8)

No	103 (59.2)

Type of diabetic complication	Neuropathy	31 (43.7)

Retinopathy	10 (14.1)

Retinopathy + Neuropathy	28 (39.4)

Retinopthy + Neuropathy + Nephropathy	2 (2.8)

Variable category	Characteristics	n (%)

Type of diabetic complication	Retinopathy	10 (14.1)

Retinopathy + Neuropathy	28 (39.4)

Retinopthy + Neuropathy + Nephropathy	2 (2.8)


Brand name	Manufacturing country	Manufacturing date	Expiring date

Ciprocin 500	Bangladesh	September 2015	September 2017

Beuflox 500	Bangladesh	June 2015	May 2017

Neofloxacin 500	Bangladesh	August 2015	August 2018

Ciprox 500	Bangladesh	August 2015	August 2018

Quinox 500	Bangladesh	February 2015	February 2018

Flontin 500	Bangladesh	September 2015	September 2018

Floxabid 500	Bangladesh	May 2015	May 2018

Cipro A 500	Bangladesh	March 2015	March 2018

Ciprozid DS 500	Bangladesh	June 2015	June 2018

Rocipro 500	Bangladesh	April 2015	April 2018

Brand name	Manufacturing country	Manufacturing date	Expiring date

Ciprocin 500	Bangladesh	September 2015	September 2017

Beuf	Banglad	June 2	Ma

Brand name	Manufacturing country	Manufacturing date	Expiring date

lox 500	esh	015	y 2017

Neofloxacin 500	Bangladesh	August 2015	August 2018

Ciprox 500	Bangladesh	August 2015	August 2018

Quinox 500	Bangladesh	February 2015	February 2018

Flontin 500	Bangladesh	September 2015	September 2018

Floxabid 500	Bangladesh	May 2015	May 2018

Cipro A 500	Bangladesh	March 2015	March 2018

Ciprozid DS 500	Bangladesh	June 2015	June 2018

Rocipro 500	Bangladesh	April 2015	April 2018


Compounds	Street	Alley	Relative Difference a (%)	Wilcoxon p-Value b	Correlation Coefficient c


Information	Number of bits

Outgoing neighbours	4

Hash function number	3

Quotient value	33

Information	Number of bits

Hash function number	3

Quotient value	33


Inclusion	Exclusion

Severe illness requiring intensive care	Substituted hypothyroidism (E03.0, E03.1, E03.3 E03.9, E89.0) or substitution in case of thyroid carcinoma (C73)

Stay of at least 24 hours at the ICU	Hyperthyroidism treated with thyrostatic agents and exhibiting a TSH level not below the reference region (E05.0 E05.9, E06.2)

	Manifest AIDS disease (B24)

	Pregnancy


	Group A	Group B

Symptoms score (NIH-CPSI questionnaire 0–43) (±S.D.)

Baseline	21.85 ± 5.23	22.56 ± 5.78

2 months	12.00 ± 4.34	5.23 ± 2.76

4 months	10.48 ± 4.14	4.11 ± 2.32


Candidates	Anatomical evidence to ARC or Kiss1 neurons	ICV or electrophysiology studies	Receptors expressed in Kiss1 neurons	Physiological relevance

Agouti-related peptide/neuropeptide Y (AgRP/NPY)	AgRP neurons formed synaptic connections with Kiss1ARC neurons (mice) (135)	Channel rhodopsin-assisted mapping indicated AgRP neurons formed inhibitory synaptic connections with Kiss1ARC neurons (mice) (135)	Npy1r, Npy2r and Npy5r (82)	Chemogenetic activation of AgRP neurons inhibited fertility in vivo (135)

Arginine vasopressin (AVP)	AVP-immunoreactive fibers in close apposition with Kiss1RP3V neurons (hamsters) (32)	AVP-stimulated Kiss1RP3V neurons (105)	Avp1r in Kiss1RP3V neurons (32, 105)	Circadian AVP signaling on Kiss1RP3V neurons is facilitated by estrogen during LH surge (32, 105)

Corticotropin-releasing hormone (CRH)	Close appositions of CRH-immunoreactive fibers and Kiss1 neurons (125)	1. Central administration of CRH suppressed LH secretion in rats (117).2. CRH stimulated LH and increased GnRH pulse amplitude in sheep (118, 119)	CRHR (125)	Possible regulator of GnRH secretion in stress-induced reproductive disorders

Dynorphin (DYN)	DYN-immunoreactive fibers in close apposition with Kiss1ARC neurons (rats and sheep) (171, 172)	ICV injection of dynorphin in adult male rats suppressed LH secretion (71)	Oprk1 or KOR (39, 59, 73)	Inhibitory

Ghrelin		1. ICV administration inhibited LH secretion (rats and sheep) (143, 144).2. Ghrelin acts on a subset of Kiss1ARC neurons and estradiol increases the sensitivity of these neurons to ghrelin signals (mice) (147)	Ghsr or GHSR1A (147)	Inhibitory

Leptin		ICV leptin treatment to fasted adult rats increased LH pulse frequency, amplitude, and mean levels (140)	Lepr (83, 141)	Kiss1 neurons are indirect target of leptin during puberty onset (142)

Neurokinin B (NKB)	NKB-immunoreactive fibers in close apposition with Kiss1ARC neurons (rats and sheep) (65, 172)	NKB increased action potential firing of Kiss1ARC neurons via activation of NK3R (57–59)	NK1 tachykinin receptor (NK1R), NK2R and NK3R (58)	Stimulatory

Pituitary adenylate cyclase-activating peptide (PACAP)	Channel rhodopsin-assisted mapping indicated PACAP neurons from the PMV synapses onto Kiss1 neurons (mice) (81)	1. ICV administered PACAP depressed plasma LH amplitude and pulse frequency in gonadectomized ewes (75).2. PACAP elevated the plasma LH levels in male rats (76).3. PMV PACAP neurons formed stimulatory synapses with Kiss1 neurons (mice) (81)	Adcyap1r1 (81, 82)	Critical for ovulatory cycling and fertility in females, acts as permissive role for leptin or nutritional regulation of reproductive function (81)

Proopiomelanocortin/Cocaine- and amphetamine-regulated transcript	Appositions between α-MSH fibers and Kiss1ARC neurons (rats and sheep) (131, 134)	Central alpha-MSH can stimulate or inhibit LH secretion in rats (129, 130)	MC4R (134)	Kiss1ARC neurons relay the stimulatory effects of melanocortin signaling onto the reproductive axis during puberty (134)

Relaxin-3	Dense relaxin-3-immunoreactive fibers projecting to the ARC (mice) (103)	ICV administration of human relaxin-3 in adult male rats stimulated LH secretion (102)	Rxfp 1 (82)	Stimulatory

RFamide-related peptide-3 (RFRP-3)	RFRP-3-immunoreactive fibers contacted Kiss1 neurons (mice and rats) (33, 90)	1. ICV RFRP-3 injection inhibits LH secretion in rats (91, 92), whereas it had no effects (97) in ewes.2. Stimulates LH secretion in male hamsters (94, 95), but inhibits LH release in females (87, 93)	Gpr147 or Npffr1 (33, 90)	Primary central target for the inhibitory action of melatonin signal on reproductive function (98)

Somatostatin (SST)	Appositions between SST-immunoreactive fibers and Kiss1 neurons (sheep) (85)	Inhibits episodic LH secretion during anestrus in sheep (84).	Sstr1, 2, 3, and 5 (82)	Inhibitory

Substance P (SP)	SP-immunoreactive fibers in close apposition with Kiss1ARC neurons (monkey) (70)	1. ICV administration of SP showed increased LH release (67).2. SP activates Kiss1ARC neurons (58)	Tacr1 or NK1R (68)	Stimulatory; critical in sustaining reproductive capabilities in female mice (66)


Body Site	TPS Technique	Energy

Brain	3D	6 MV, 6 MV FFF

Brain	IMRT, VMAT	6 MV

Whole Brain	3D	6 MV

Head and Neck bilateral	3D, IMRT, VMAT	6 MV

Lung ‐ Left upper lobe	3D, IMRT	6 MV

Body Site	TPS Technique	Energy

Lung ‐ Left upper lobe	3D, IMRT	6 MV


Peak a	Carotenoid	tR b (min)	λmax c (nm)	% III/II	% AB/AII	[M + H]+ (m/z)	MS/MS fragment ions (positive mode) (m/z)	[M − H]− (m/z)	MS/MS fragment ions (negative mode)(m/z)

26	crustaxanthin	7.9	422, 449, 476	40	0	601	583 [M + H − 18]+, 565 d [M + H − 18 − 18]+, 547 [M + H − 18-18-18]+, 509 [M + H − 92]+	599	581 [M − 18]−, 563 [M − 18 − 18]−, 545 [M − 18 − 18 − 18]−, 507 [M − 92]−, 493 [M − 106]−


Characteristic	Variable	Case

Gender	Male	24165

	Female	19825

Site	Colon	23563

	Rectal	20427

Colon	Proximal	7588

	Distal	7305

	unknown	8670

Pathologic classification	Adenocarcinoma	30845

	Mucinous carcinoma	1716

	Other types	1014

	unknown	10415


Sample	Source	UId	Sex	Age	Mutation

					nt change	aa change	domain affected	type of mutation

RTT1	HBTRC	4315	F	11	c.763C>T	R255X	TRD-NLS	Nonsense

RTT3	HBTRC	4422	F	12	c.808C>T	R270X	TRD-NLS	Nonsense

RTT4	TICHR	NB	F	18	c.473C>T	T158M	MBD	Missense

RTT5	TICHR	KB	F	11	c.316C>T	R106W	MBD	Missense

RTT6	TICHR	BC	F	21	c.808C>T	R270X	TRD-NLS	Nonsense

RTT9	BCM	93-244	F	4	c.750insC	P251fs	TRD	Frameshift/Truncation

CON4	NSWTRC	88210	F	43

CON5	NSWTRC	88295	F	42

CON6	NSWTRC	88365	F	31

CON7	NSWTRC	88304	F	43

CON8	NSWTRC	9092	F	46

CON10	NSWTRC	12862	F	52

Sample	Source	UId	Sex	Age	Mutation

RTT9	BCM	93-244	F	4	c.750insC	P251fs	TRD	Frameshift/Truncation

CON4	NSWTRC	88210	F	43

CON5	NSWTRC	88295	F	42

CON6	NSWTRC	88365	F	31

CON7	NSWTRC	88304	F	43

CON8	NSWTRC	9092	F	46

CON10	NSWTRC	12862	F	52


Question	HCW category Total, (%)

MDs (n = 20)

Whether facility is equipped to handle EVD cases

Yes	4 (3.96)

No	14 (13.86)

I don’t know	2 (1.98)

Whether health staff agrees to be isolated or not

Yes	19 (18.81)

No	0 (0)

Maybe	1 (0.99)

Willingness to attend to an EVD patient

Yes	9 (8.91)

No	6 (5.94)

Maybe	5 (4.95)

Whether health staff is adequately trained or not

Yes	1 (0.99)

No	19 (18.81)

Confidence level in handling an EVD suspected patient

No confidence	3 (2.97)

Little confidence	10 (9.90)

Confident	3 (2.97)

Very confident	3 (2.97)

Extremely confident	1 (0.99)


Characteristics

n

Age (years)a

Female/male (% female)

Follow-up time (years)a

Clinical presentation

Optic neuritis

Brainstem

Spinal

Others

CSF cellsb

Proteins (mg/dL)b


Variable	Definition

Taxonomic class	Within this example we adopt the designation of taxonomic Specification from the NCBI's taxonomy database [63].

Injection.chemical	The chemical molecule injected into the brain of an animal as part of a tract-tracing experiment. These reagents are not confined to a specific type of chemical simply have the property of when injected into brain tissue, they are taken up and transported along axons by active processes in neurons. Early examples of these include tritiated amino acids [64], Horseradish peroxidase (HRP) [65] and notably Phaseolus Leuco-Agglutinin [66]. Tracer chemicals include fluorescent dyes and beads and even include more exotic materials such as viruses and Cholera Toxin. See [17,67-71] for reviews of the general and specialized methods used.

Injection.location	This refers to the extent of the complete injection site expressed in terms of its spatial relationships to identified brain structures from the Swanson atlas [32] and encoded into the neuroanatomical nomenclature specified from the BAMS system [72]

Mapped location	Similarly to Injection.location, this refers to the spatial extent of an individual region of labeling (judged by the scientist reporting the study to be relatively homogeneous) expressed in terms of its spatial relationships to named neuroanatomical terms from the BAMS ontology [72]

Labeling.type	A simple categorization of the part of the neuron that is labeled. This is a nominal data element with possible values 'cellular' (denoting that the neuronal cell bodies were labeled), ' fibers' (denoting that axonal fibers were labeled), or 'terminals' (denoting that axonal fibers with characteristics of a terminal region were labeled, including heavy branching and the presence of boutons).

Labeling.density	A simple, seven point ordinal scale with the following categories (in order): 'no label', 'very sparse label, 'sparse label', 'sparse/moderate label', 'moderate label', 'moderate/dense label' and 'dense label'. We also include an additional category to denote that labeling is present but with an unknown density.


	Preoperative model	Postoperative model	Intra-ICU model

(Constant)	1.26	0.44	1.82

Expected session time (min)	1.10 (1.01–1.21)

Patient age (per decade)	1.16 (1.06–1.28)	1.20 (1.09–1.31)	1.09 (1.02–1.17)

FEV1 (l)	0.91 (0.81–1.03)	0.85 (0.75–0.96)

Gastroesophageal reflux disease (yes/no)	1.46 (1.14–1.89)	1.53 (1.19–1.96)

Vascular comorbidity (yes/no)	1.29 (1.01–1.66)	1.32 (1.03–1.69)

Neurological comorbidity (yes/no)	1.74 (1.24–2.43)	1.82 (1.31–2.53)

Previous chemotherapy (yes/no)	0.81 (0.68–0.97)

Previous radiotherapy (yes/no)			0.78 (0.63–0.97)

Transthoracic approach (yes/no)	2.13 (1.74–2.62)	1.79 (1.44–2.24)	1.21 (1.05–1.40)

Reconstruction using colon (yes/no)	1.56 (1.05–2.30)	1.52 (1.03–2.23)

Observed session time (min)		1.07 (0.98–1.16)

Volume administration of colloids (liter)		1.14 (1.01–1.29)

Absolute intraoperative blood loss (l)		0.94 (0.87–1.02)

Absolute intraoperative urine production (l)		1.12 (0.99–1.25)

Epidural analgesia administration (yes/no)		0.83 (0.69–1.01)

Respiratory minute volume (l)		1.09 (1.04–1.15)	1.05 (1.01–1.09)

Positive end-expiratory pressure (cmH2O)		1.03 (0.99–1.07)

Chylothorax surgical complication (yes/no)			1.31 (0.96–1.79)

Anastomosis leakage complication (yes/no)			1.83 (1.47–2.28)

Other complication (yes/no)			1.71 (1.38–2.10)

Pulmonary nonsurgical complication (yes/no)			1.97 (1.72–2.26)

Myocardial infarction (yes/no)			1.54 (0.93–2.56)

Infection (yes/no)			1.61 (1.25–2.07)

Other nonsurgical complication (yes/no)			1.41 (1.22–1.62)

Multiple r2	21%	25%	56%

Optimism	6%	9%	11%

Optimism corrected r2	15%	17%	45%

	Preoperative model	Postoperative model	Intra-ICU model

(Constant)	1.26	0.44	1.82

Expected session time (min)	1.10 (1.01–1.21)

Patient age (per decade)	1.16 (1.06–1.28)	1.20 (1.09–1.31)	1.09 (1.02–1.17)

FEV1 (l)	0.91 (0.81–1.03)	0.85 (0.75–0.96)

Gastroesophageal reflux disease	1.46 (1.14–1.89

	Preoperative model	Postoperative model	Intra-ICU model

 (yes/no)	)	1.53 (1.19–1.96)

Vascular comorbidity (yes/no)	1.29 (1.01–1.66)	1.32 (1.03–1.69)

Neurological comorbidity (yes/no)	1.74 (1.24–2.43)	1.82 (1.31–2.53)

Previous chemotherapy (yes/no)	0.81 (0.68–0.97)

Previous radiotherapy (yes/no)			0.78 (0.63–0.97)

Transthoracic approach (yes/no)	2.13 (1.74–2.62)	1.79 (1.44–2.24)	1.21 (1.05–1.40)

Reconstruction using colon (yes/no)	1.56 (1.05–2.30)	1.52 (1.03–2.23)

Observed session time (min)		1.07 (0.98–1.16)

Volume administration of colloids (liter)		1.14 (1.01–1.29)

Absolute intraoperative blood loss (l)		0.94 (0.87–1.02)

Absolute intraoperative urine production (l)		1.12 (0.99–1.25)

Epidural analgesia administration (yes/no)		0.83 (0.69–1.01)

Respiratory minute volume (l)		1.09 (1.04–1.15)	1.05 (1.01–1.09)

Positive end-expiratory pressure (cmH2O)		1.03 (0.99–1.07)

Chylothorax surgical complication (yes/no)			1.31 (0.96–1.79)

Anastomosis leakage complication (yes/no)			1.83 (1.47–2.28)

Other complication (yes/no)			1.71 (1.38–2.10)

Pulmonary nonsurgical complication (yes/no)			1.97 (1.72–2.26)

Myocardial infarction (yes/no)			1.54 (0.93–2.56)

Infection (yes/no)			1.61 (1.25–2.07)

Other nonsurgical complication (yes/no)			1.41 (1.22–1.62)

Multiple r2	21%	25%	56%

Optimism	6%	9%	11%

Optimism corrected r2	15%	17%	45%


Variable, n (%)

Gender (female) n=821*

Age: n= 819*

>−25

25-35

35-45

45-55

55-<

Born not in Sweden, n=819*

Profession: n=798*

Health care staff

Administrative staff

Food staff

Others:


Concentration	EAC Control	PST 200 mg/kg	5-FU 20 mg/kg	PST + 5-FU

Tumor volume (mL)	9.7 ± 0.2	4.4 ± 0.34***	3.3 ± 0.6***	2.9 ± 0.29***


Comparison	CYP19A1 vs. RORA*	A2BP1 vs. RORA	ITPR1 vs. RORA	NLGN1 vs. RORA

Correlation coefficient	0.99	0.83	0.72	0.81

P val (2-tailed)	0.03	0.38	0.49	0.39

R2	0.99	0.69	0.52	0.66

Comparison	CYP19A1 vs. RORA*

Correlation coefficient	0.99

P val (2-tailed)	0.03

R2	0.99


Characteristic	N (%)

Sex

Male	58 (61.1)

Female	36 (38.8)

Missing	1 (1.1)

Work-place

Ministry of Health	15 (15.7)

Tertiary/referral hospital	32 (33.7)

University	27 (28.4)

NGO	20 (21.1)

Missing	1 (1.1)

Training completed

Bachelor of medicine/MD	59 (62.1)

Postgraduate training/MMED	8 (8.4)

MS/MPH	12 (12.6)

PhD	2 (2.1)

*Other	13 (13.7)

Missing	1(1.1)

Current training

Postgraduate training/MMED	17 (18.9)

MS/MPH	16 (16.8)

PhD in a health related field (e.g. epidemiology or Health Services Research)	23 (24.2)

**Other	38 (40.0)

Missing	1 (1.1)

Characteristic	N (%)

Sex

Male	58 (61.1)


Risk Factors	Odds Ratio for Anti-HEV IgM, 95% CI	P value†	Odds Ratio for Anti-HEV IgG, 95% CI	P valueγ

CD4+ count >200cells/μl	5.109 [1.624–16.070]	0.005*	0.67 [.333–1.36]	0.273


ID #	Age (yr)	Sex	RBT (w)	Symptoms	HP	ED	GH	PU	AD	RD

1	5.9	M	4					Severe

2	13.4	M	3	Arthralgia				Mild

3	5.4	M	6		+		+	Severe

4	5.4	M	3					Severe

5	10.8	F	3	Abdominal pain	+			Moderate

6	10.6	M	9			+		Severe	+

7	7.9	F	3			+		Severe	+

8	12.0	F	6		+		+	Severe	+

9	7.7	F	12	Abdominal pain, arthralgia,		+		Moderate

10	9.1	M	3	Abdominal pain, arthralgia,	+	+	+	Severe		+

11	9.2	M	2	Arthralgia	+			Severe


Demographic category	N (%)

N	1184

Age (m,sd)	66.6 (10.8)

Age

18-45	45 (3.8)

46-60	281 (23.7)

61-70	394 (33.3)

71-80	346 (29.3)

81+	114 (9.7)

Gender

Male	720 (60.9)

Marital status

Single	118 (10.0)

Married/partner	891 (75.2)

Divorced	74 (6.3)

Widowed	99 (8.4)

Length of time with diabetes

< 5 years	612 (51.7)

> = 5 years	572 (48.3)

Diabetes management

Diet	321 (27.1)

Tablets	711 (60.1)

Insulin	148 (12.5)

Health status

Diabetes related complications	None	710 (61.3)

One or more	448 (38.7)

Feet	257 (21.7)

Eyes	266 (22.5)

Kidneys	66 (5.6)

Other health complications	None	216 (18.5)

One or more	952 (81.5)

Arthritis	503 (43.2)

Hypertension	513 (44.1)

High cholesterol	588 (50.5)

Heart conditions	108 (11.4)

Depression/anxiety	207 (17.8)

EQ-5D index score	0.652 (0.32)

SF-6D index score	0.693 (0.16)

DHP-18 PD	17.93 (20.5)

BA	21.53 (19.31)

DE	35.93 (23.04)

Change in health baseline-follow up

Health improvement	186 (15.9)

No change	717 (61.7)

Health deterioration	260 (22.4)


Parameter	Value

General assumptions for the facility

rBuChE production level 	25 kg rBuChE/year (bulk)

rBuChE doses per year	62,500 doses/year at 400 mg/dose

Downstream Recovery/purification yield	20%

Annual operating days	330 days

rBuChE production in plants following infiltration/incubation	125 kg rBuChE/year

Batch cycle time (time between start of new infiltration batches)	7 days

Batches per year	47

Base case rBuChE expression level	500 mg/kg FW at ~7 days after infiltration

Facility lifetime	15 years

Depreciation	Straight line over 10 years, 5% direct fixed capital salvage

Working capital	30 days of labor, materials, utilities, waste treatment

Lab/QC/QA costs	2% of total labor costs for plant growth and agroinfiltration sections, 15% of total labor costs for recovery and purification section

Start-up/validation costs	5% direct fixed capital

Assumptions for indoor plant growth section

Mass per plant at 5 weeks	0.02 kg FW/plant

Tray size	4 ft × 4 ft

Number of plants per tray	256

Tobacco seed cost	$0.001/seed

Age at infiltration	4 weeks

Total number of plant batches in inventory	5 batches (just seeded, 1 wk old, 2 wk old, 3 wk old, 4 wk old—ready to infiltrate, 5 wk old—infiltrated, incubated and ready to harvest)

Total number of plants in inventory	~1.3 million

Total plant growth area	83,320 ft2 total, or 10 levels with 8,332 ft2 footprint

LED fixture costs	$40/ft2 plant growth area (including capital cost factors for plant growth area as shown in Table 2)

LED energy costs	20 W/ft2

Assumptions for Agrobacterium production, vacuum infiltration, and plant incubation section

Agro “loading”—mass of recombinant Agrobacterium to mass of plant tissue	0.00001 kg dry weight (dw) bacteria/kg FW plant biomass

Agrobacterium biomass density at 12 hours of culture	2.6 g dw/L = 0.0026 kg dw/L

Inoculum density used in seed train	1% V/V

Dilution factor between agroinfiltration solution and agrobacterial production fermentor	78

Percent weight change in plant tissue following vacuum agroinfiltration	30%

Trays processed per vacuum chamber (30 ft) per day	336 trays/chamber/day

“Excess” Agrobacterium solution used	87% of total infiltration solution

Incubation time for infiltrated plants	~7 days

Assumptions for the rBuChE recovery and purification section

Overall yield in downstream processes	20%

Harvesting rate	3 trays/minute

IEX chromatography

 Binding capacity	20 mg/mL

 Resin cost	$1,839/L

 Number of reuse cycles	100

Affinity chromatography

 Binding capacity	3 mg/mL

 Resin cost	$10,000/L

 Number of reuse cycles	30

Parameter	Value

Dilution factor between agroinfiltration solution and agrobacterial production fermentor	78

Percent weight change in plant tissue following vacuum agroinfiltration	30%

Trays processed per vacuum chamber (30 ft) per day	336 trays/chamber/day

“Excess” Agrobacterium solution used	87% of total infiltration solution

Incubation time for infiltrated plants	~7 days

Assumptions for the rBuChE recovery and purification section

Overall yield in downstream processes	20%

Harvesting rate	3 trays/minute

IEX chromatography

Binding capacity	20 mg/mL

Resin cost	$1,839/L

Number of reuse cycles	100

Affinity chromatography

Binding capacity	3 mg/mL

Resin cost	$10,000/L

Number of reuse cycles	30


	Value	Alternative Indicator

Waist circumference	* >94 cm in males, >80 cm in females** >102 cm in males, >88 cm in females

Raised blood pressure	Systolic ≥130 and/or diastolic ≥85 mm Hg	Treatment of previously diagnosed hypertension

Raised FPG	≥100 mg/dL (5.6 mmol/L)	Previously diagnosed of T2DM

Raised TG	>150 mg/dL (1.7 mmol/L)	Specific pharmacological treatment

Reduced HDL-C	<40 mg/dL (1.0 mmol/L) in males<50 mg/dL (1.3 mmol/L) in females	Specific pharmacological treatment

Waist circumference

Raised blood pressure

Raised FPG

Raised TG

Reduced HDL-C

Value	Alternative Indicator

* >94 cm in males, >80 cm in females** >102 cm in males, >88 cm in females

Systolic ≥130 and/or diastolic ≥85 mm Hg	Treatment of previously diagnosed hypertension

≥100 mg/dL (5.6 mmol/L)	Previously diagnosed of T2DM

>150 mg/dL (1.7 mmol/L)	Specific pharmacological treatment

<40 mg/dL (1.0 mmol/L) in males<50 mg/dL (1.3 mmol/L) in females	Specific pharmacological treatment


Probe Set	z-score	DMFS	Gene Symbol	Gene Title

208905_at	4.29	-	CYCS	cytochrome c, somatic

204817_at	3.73	-	ESPL1	extra spindle poles like 1

38158_at	3.41	-	ESPL1	extra spindle poles like 1

204947_at	3.04	-	E2F1	E2F transcription factor 1

201111_at	3.04	-	CSE1L	CSE1 chromosome segregation 1-like

201636_at	2.97	-	FXR1	fragile X mental retardation, autosomal homolog 1

220048_at	2.82	-	EDAR	ectodysplasin A receptor

210766_s_at	2.75	-	CSE1L	CSE1 chromosome segregation 1-like

221567_at	2.66	-	NOL3	nucleolar protein 3 (apoptosis repressor with CARD domain)

213829_x_at	2.65	-	TNFRSF6B	tumor necrosis factor receptor superfamily, member 6b, decoy

201112_s_at	2.57	-	CSE1L	CSE1 chromosome segregation 1-like

212353_at	2.51	-	SULF1	sulfatase 1

208822_s_at	2.47	-	DAP3	death associated protein 3

209462_at	2.37	-	APLP1	amyloid beta (A4) precursor-like protein 1

203005_at	2.29	-	LTBR	lymphotoxin beta receptor (TNFR superfamily, member 3)

202731_at	4.01	+	PDCD4	programmed cell death 4

206150_at	3.57	+	TNFRSF7	tumor necrosis factor receptor superfamily, member 7

202730_s_at	3.18	+	PDCD4	programmed cell death 4

209539_at	3.14	+	ARHGEF6	Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6

212593_s_at	3.07	+	PDCD4	programmed cell death 4

204933_s_at	2.96	+	TNFRSF11B	tumor necrosis factor receptor superfamily, member 11b

209831_x_at	2.43	+	DNASE2	deoxyribonuclease II, lysosomal

203187_at	2.38	+	DOCK1	dedicator of cytokinesis 1

210164_at	2.34	+	GZMB	granzyme B

robe Set	score	MFS	 Symbol	 Title

208905_at	4.29	-	CYCS	cytochrome c, somatic

204817_at	3.73	-	ESPL1	extra spindle poles like 1

38158_at	3.41	-	ESPL1	extra spindle poles like 1

204947_at	3.04	-	E2F1	E2F transcription factor 1

201111_at	3.04	-	CSE1L	CSE1 chromosome segregation 1-like

201636_at	2.97	-	FXR1	fragile X mental retardation, autosomal homolog 1

220048_at	2.82	-	EDAR	ectodysplasin A receptor

210766_s_at	2.75	-	CSE1L	CSE1 chromosome segregation 1-like

221567_at	2.66	-	NOL3	nucleolar protein 3 (apoptosis repressor with CARD domain)

213829_x_at	2.65	-	TNFRSF6B	tumor necrosis factor receptor superfamily, member 6b, decoy

201112_s_at	2.57	-	CSE1L	CSE1 chromosome segregation 1-like

212353_at	2.51	-	SULF1	sulfatase 1

208822_s_at	2.47	-	DAP3	death associated protein 3

209462_at	2.37	-	APLP1	amyloid beta (A4) precursor-like protein 1

203005_at	2.29	-	LTBR	lymphotoxin beta receptor (TNFR superfamily, member 3)

202731_at	4.01	+	PDCD4	programmed cell death 4

206150_at	3.57	+	TNFRSF7	tumor necrosis factor receptor superfamily, member 7

202730_s_at	3.18	+	PDCD4	programmed cell death 4

209539_at	3.14	+	ARHGEF6	Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6

212593_s_at	3.07	+	PDCD4	programmed cell death 4

204933_s_at	2.96	+	TNFRSF11B	tumor necrosis factor receptor superfamily, member 11b

209831_x_at	2.43	+	DNASE2	deoxyribonuclease II, lysosomal

203187_at	2.38	+	DOCK1	dedicator of cytokinesis 1

210164_at	2.34	+	GZMB	granzyme B


	Connecticut (n = 631 visits) %	Washington (n = 1186 visits) %

Gender

 female	76	74

Age

 Median	43 years	42 years

 0–15 years	12.8	10.9

 16–34 years	16.4	20.9

 35–64 years	63.0	58.5

 65 years+	7.8	9.7

Race

 White	97	96

Smoking status:

 non-smokers	95	94

Type of major problema

 Acute problem	22	23

 Chronic problem, routine	53	56

 Chronic problem, flare up	20	18

 Pre/post-surgery/injury	1	1

 Non-illness care	5	6

Primary reason for visitb

 Fatigue	6.1	6.0

 Headache	4.4	3.8

 Back symptoms	4.4	6.5

 Skin rashes	4.2	2.5

 Menopausal symptoms	3.7	2.0

 Bowel function changes	3.5	2.0

 Anxiety or Depression	3.2	5.1

 Allergies to food, milk	3.0	3.6

 Sinus symptoms	2.8	<2

 Upper respiratory symptoms	2.6	<2

 Cough	2.4	<2

 Neck symptoms	2.3	3.3

 Infectious disease	2.2	<2

 Ear infection symptoms	2.2	<2

 Abdominal pain/cramps	2.2	2.7

 Menstrual problems	<2	2.1

Diagnosis by naturopathic physicianc

 Menopausal disorders	4.9	3.1

 Allergies	4.6	6.3

 Back conditions	3.5	5.8

 Fibromyalgia	3.0	2.0

 Sinusitis	2.9	<2

 Fatigue	2.4	2.7

 Headache	2.2	3.1

 Upper respiratory infections	2.0	<2

 Neck conditions	<2	3.3

 Depression	<2	2.6

 Asthma	<2	2.2

 Anxiety	<2	2.1

 Dermatitis	<2	2.0

New patients	22	22

Payment

 Private insurance	60	43

 Worker's compensation	0	3

 Personal injury	0	3

 Self-pay	37	48

 Other	3	3

	Connecticut (n = 631 visits) %	Washington (n = 1186 visits) %

16–34 years	16.4	20.9

35–64 years	63.0	58.5

65 years+	7.8	9.7

Race

White	97	96

Smoking status:

non-smokers	95	94

Type of major problema

Acute problem	22	23

Chronic problem, routine	53	56

Chronic problem, flare up	20	18

Pre/post-surgery/injury	1	1

Non-illness care	5	6

Primary reason for visitb

Fatigue	6.1	6.0

Headache	4.4	3.8

Back symptoms	4.4	6.5

Skin rashes	4.2	2.5

Menopausal symptoms	3.7	2.0

Bowel function changes	3.5	2.0

Anxiety or Depression	3.2	5.1

Allergies to food, milk	3.0	3.6

Sinus symptoms	2.8	<2

Upper respiratory symptoms	2.6	<2

Cough	2.4	<2

Neck symptoms	2.3	3.3

Infectious disease	2.2	<2

Ear infection symptoms	2.2	<2

Abdominal pain/cramps	2.2	2.7

Menstrual problems	<2	2.1

Diagnosis by naturopathic physicianc

Menopausal disorders	4.9	3.1

Allergies	4.6	6.3

Back conditions	3.5	5.8

Fibromyalgia	3.0	2.0

Sinusitis	2.9	<2

Fatigue	2.4	2.7

Headache	2.2	3.1

Upper respiratory infections	2.0	<2

Neck conditions	<2	3.3

Depression	<2	2.6

Asthma	<2	2.2

Anxiety	<2	2.1

Dermatitis	<2	2.0

New patients	22	22

Payment

Private insurance	60	43

Worker's compensation	0	3

Personal injury	0	3

Self-pay	37	48

Other	3	3


Scopus	Query	Research in:	Items found

#1	“Sensory integration” OR “multisensory integration” OR “crossmodal integration” OR “cross-modal integration” OR “intersensory integration” OR “multimodal integration” OR “crossmodal illusion*” OR “cross-modal illusion*” OR multisensory OR crossmodal OR cross-modal OR “crossmodal sensory integration” OR “cross-modal sensory integration” OR “multisensory interaction*”	Article Title, Abstract, Keywords	11,005

#2	Measurement* OR Test* OR performance OR assessment* OR “Test development” OR “task performance” OR “disability evaluation” OR “Feasibility studies” OR validity OR reliability OR study* OR results*	Article Title, Abstract, Keywords	14,411,633

#3	Combine #1 AND #2		5127

#4	Limit to (Humans OR human) AND (Limit to (DOCTYPE, article))		3241

#5	Limit to (“aged”, “aging”)		394

#6	Exclude (“Speech perception”, “Speech Perception”, “Speech”)		351

#7	Exclude (“Alzheimer Disease”, “Alzheimer disease”, “Parkinson Disease”, “Parkinson disease”, “Aphasia”, “Dementia”, “Disease severity”, “Brain damage”, “Brain injury”, “Stroke”, “Neglect”, “Brain damage, chronic”, “Cerebrovascular accident”, “Cognition disorders”, “Neurologic disease”, “Schizophrenia”)		308

Scopus	Query	Research in:	Items found

#6	Exclude (“Speech perception”, “Speech Perception”, “Speech”)		351

#7	Exclude (“Alzheimer Disease”, “Alzheimer disease”, “Parkinson Disease”, “Parkinson disease”, “Aphasia”, “Dementia”, “Disease severity”, “Brain damage”, “Brain injury”, “Stroke”, “Neglect”, “Brain damage, chronic”, “Cerebrovascular accident”, “Cognition disorders”, “Neurologic disease”, “Schizophrenia”)		308